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Abstract 
 
A Mail Survey to Assess the Incidence and Impact of Drug Shortages 
within Texas Non – Government Acute Care Hospitals 
 
Tawfik Rajab Rajab, M.S.Phr. 
The University of Texas at Austin, 2013 
 
Supervisor:  Marvin D. Shepherd 
 
The objective of this study was to explore the incidence and impact of drug 
shortages within Texas Non-Government Acute Care Hospitals. A self-administered mail 
survey instrument was used to collect data. A convenience sample of 321 pharmacy 
directors of non-government acute care hospitals in the state of Texas was selected from 
the Texas Department of State Health Services (DSHS) Hospital List for 2012.  
A total of 125 completed surveys were received by mail and 8 surveys were 
returned as undelivered, resulting in a response rate of 39.84% (125/313). A total of 56 
(45.5%) respondents reported 11 or more drug shortages for the month of April 2013. 
There was a significant association between the number of drug shortages experienced 
and hospital size (p = 0.003), inpatient medication budget (p = 0.001) and hospital 
location (p=0.015). Of the 124 respondents, 78 (62.9%) spent four to 12 hours a week on 
managing drug shortage situations. There was a significant association between the 
number of hours spent per week by hospital pharmacy personnel when managing drug 
 vii 
shortages controlling for hospital size (p < 0.001), number of drug shortages experienced 
(p < 0.001), number of pharmacist FTEs (p < 0.001), and number of pharmacy technician 
FTEs (p < 0.001). A total of 107 (85.6%) reported that grey market vendors have 
contacted hospital pharmacy personnel in the month of April, 2013. A total of 96 (76.8%) 
‘strongly agreed’ that grey market vendors are more likely to contact health care facility 
when drug shortage exists, 110 (88%) ‘strongly agreed’ that grey market vendors sell 
drugs in short supply at inflated prices and 70 (56%) ‘strongly agreed’ that the practice of 
buying drug products from grey market vendors should be eliminated. 
In summary, all surveyed hospitals experienced at least one drug shortage for the 
month of April 2013, pharmacy personnel devoted a significant amount of time managing 
drug shortages and the majority of the hospitals were contacted by grey market vendors 
with the aim of selling drugs in short supply.  
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Chapter One: Introduction and Literature Review 
 
1.1 INTRODUCTION 
Drug shortages have been on the rise since 2001.1 Beginning in 1996, the 
University of Utah Drug Information Service (UUDIS) started reporting drug shortages 
to practitioners at University of Utah Hospitals and Clinics (UUHSC). Later, in 2001, 
UUDIS initiated tracking drug shortages on a national level by providing information to 
the American Society of Health System Pharmacists (ASHP). According to UUDIS 
database, there was a considerable increase in the number of drug shortages from 3 in 
1996 to 119 in 2001.2 In 1999, the U.S. Food and Drug Administration (FDA) started the 
Drug Shortage Program (DSP) within the Center for Drug Evaluation and Research 
(CDER) reporting 61 drug product shortages in 2005 and 178 in 2010.3 Yet, ASHP/ 
UUDIS reported 74 drug shortages in 2005 and 211 in 2010.4 These discrepancies in the 
numbers reported are due to the fact that FDA and ASHP define drug shortages 
differently. FDA defines drug shortage as “a situation in which the total supply of all 
clinically interchangeable versions of an FDA-regulated drug is inadequate to meet the 
current or projected demand at the user level.”5 ASHP’s definition of a drug shortage is 
“a supply issue that affects how the pharmacy prepares or dispenses a drug product or 
influences patient care when prescribers must use an alternative agent.”6 Despite these 
differences, the number of drug shortages has been increasing over the years; 
ASHP/UUDIS reported 70 in 2006, 126 in 2007, 149 in 2008, 166 in 2009, and 211 in 
2010.7 As of the current month, March 2013, there are 121 drug shortages listed on the 
 2 
FDA Web site and 235 drug shortages reported on the ASHP Web site.8.9 Figure 1.1 
represents the number of national new drug shortages in the period between 2001 and 
2012 as reported by UUDIS.  
Figure 1.1: Number of U.S.  New Drug Shortages, 2001-2012 
Source: Fox E, Wheeler M. Drug Shortages in the US: Causes and What the FDA Is Doing to Prevent New 
Shortages. AccessMedicine from McGraw-Hill. March 2013. Available at: 
http://www.medscape.com/viewarticle/780328. Accessed June 15, 2013. 
 
Despite the decrease in the number of new drug shortages tracked in 2012, the 
number of active and ongoing drug shortages was 299 as of December 31, 2012, the 
highest for the period between 2010 and 2012. Figure 1.2 illustrates the number of active 
and ongoing national drug shortages by quarter for the period between January 2010 and 
December 2012 as reported by UUDIS. 
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Figure 1.2: Number of National Active Drug Shortages by Quarter, 2010-2012 
Source: Fox E, Wheeler M. Drug Shortages in the US: Causes and What the FDA Is Doing to Prevent New 
Shortages. AccessMedicine from McGraw-Hill. March 2013. Available at: 
http://www.medscape.com/viewarticle/780328. Accessed June 15, 2013. 
 
The issue of drug shortages has grabbed the attention of mass media, health 
professionals, patients, and politicians. As a result, President Obama issued an Executive 
Order in October, 2011 urging FDA to encourage early reporting of potential shortages 
by manufacturers, expedite reviews of applications regarding start or alter production of 
medicines, and work in collaboration with the United States Department of Justice in 
controlling price escalation of existing drug shortages.10 This was followed by the FDA 
Safety and Innovation Act (FDASIA), which was passed by the Congress in June 2012, 
requiring drug manufacturers to notify FDA when discontinuation or interruption in the 
manufacturing process of a drug occurs that could result in a shortage of that drug in the 
United States.11 
152
167
176
188
239 246
256
273
260
211
282
299
0
50
100
150
200
250
300
350
Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11 Q4-11 Q1-12 Q2-12 Q3-12 Q4-12
 4 
The following sections provide information on frequency of drug shortages, 
characteristics of drug shortages, issues affecting the supply and distribution of drug 
products, and resources available when obtaining information on drug shortages. This 
will be followed by literature review detailing the causes of drug shortages, impact of 
drug shortages on patient care, and grey market activities associated with drug shortages. 
1.1.1 Frequency of Drug Shortages 
Only a limited number of studies, in particular surveys, exist with the objective of 
collecting data on the frequency of drug shortages as experienced by health systems. The 
American Hospital Association (AHA) conducted one such survey in June 2011, 
collecting data from 820 non-federal, short-term acute care hospitals. The survey 
revealed that 99.5% of the hospitals experienced one or more drug shortage in the last six 
months, and 44% reported encountering 21 or more shortages for the same time period.12 
A survey of 1373 anesthesiologists administered by the American Society of 
Anesthesiologists (ASA) in April 2011, reported that more than 90% of the respondents 
were experiencing at least one anesthesia drug shortage currently and more than 98% had 
an incidence of anesthetic shortage in the last year.13 In 2011, ASHP performed a national 
survey of 1322  pharmacy directors looking at the impact of drug shortages on U.S. 
health systems. The study found that 47% of the institutions with 400 or more beds 
encountered more than 30 drug shortages in the year of 2010.14 Premier Healthcare 
Alliance analyzed a survey of 311 hospital pharmacists from 228 hospitals in March 2011 
claiming that 90% had experienced a drug shortage for the period between July and 
December 2010. In addition it was reported that there were more than 240 drug shortages 
and more than 400 generics that were back-ordered for five or more days.15 
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1.1.2 Characteristics of Drug Shortages 
The vast majority of drug shortages reported to FDA are prescription drugs, 
where the highest proportion involves injectable generic products. According to FDA, for 
the year of 2010 injectables accounted for 74% of all recorded drug shortages.16 
Moreover, UUDIS announced that as of September 2011, parenteral drug shortages 
contributed to 60% of the drug shortages.17 Data analysis of 127 drug shortages collected 
by the DSP for the period between January 1, 2010 and August 26, 2011, revealed that 
80% of drugs in short supply concerned injectables, 10% oral tablets/capsules and 2% for 
each of the dermal, inhalation and oral liquid preparations.18 Figure 1.3 shows the 
percentages of drug shortages according to route of administration based on data of 127 
drug shortages for the period between January 2010 and August 2011.  
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Figure 1.3: Drug Shortages by Route of Administration, January 2010-August 2011a 
Source: Food and Drug Administration. A review of FDA’s approach to medical product shortages. 2011 
October 31. Available at: www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm277745.htm. 
Accessed November 10, 2011. 
a Percentages total to 101% due to rounding.  
 
 
In addition, the examination of 127 drug shortages showed that oncology 
medicines accounted for 28% of all shortages, followed by antibiotics (13%), 
electrolyte/nutrition products (11%), neuromodulators (9%), hormones (6%), and drug 
classes with five or fewer shortages (33%).19 Figure 1.4 presents the percentages of drug 
shortages by drug class based on data of 127 drug shortages for the period between 
January 2010 and August 2011. 
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Figure 1.4: Drug Shortages by Drug Class, January 2010-August 2011 
Source: Food and Drug Administration. A review of FDA’s approach to medical product shortages. 2011 
October 31. Available at: www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm277745.htm. 
Accessed November 10, 2011. 
 
 Further study of the data demonstrated that 43% of all shortages were due to 
quality issues within the manufacturing facility, 15% due to delays in manufacturing or 
shipping, 10% due to shortage of Active Pharmaceutical Ingredient (API), and 8% due to 
business decision to discontinue production.20 Figure 1.5 represents the percentages of 
drug shortages by primary reason for disruption in production and supply based on data 
of 127 drug shortages for the period between January 2010 and August 2011. 
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Figure 1.5: Drug Shortages by Primary Reason for Disruption in Production and 
Supply, January 2010-August 2011 
 
 
Source: Food and Drug Administration. A review of FDA’s approach to medical product shortages. 2011 
October 31. Available at: www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm277745.htm. 
Accessed November 10, 2011. 
 
 
1.1.3 Issues Affecting the Supply and Distribution of Drug Products 
Prior to FDASIA of 2012, manufacturers were required to provide a six months’ 
advance notice to FDA regarding discontinuation of the production of a single-source, 
medically necessary drug. All other manufacturers provided early notifications of 
potential shortages of other drug on voluntary basis. According to FDA early warnings 
from manufacturers for potential interruptions in product supply have been critical to 
preventing drug shortages. In fact, FDA was able to prevent 195 shortages in 2011and 
100 shortages during the first half of 2012 using its authority and the early notifications 
from manufacturers.21  
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Another issue that might contribute to disruption within the supply chain of drug 
products is the practice of stockpiling. Stockpiling is the practice of the accumulation of 
drug products by purchasing more products than would be necessary to fulfill an 
institution’s monthly needs. In fact, stockpiling could extend the period within which the 
drug is in short supply because it creates an artificial depletion of a drug product in the 
supply chain.22 Therefore, ASHP recommended that health care organizations avoid 
stockpiling of drug products for the sole purpose of preventing artificial drug shortage 
and costly inventories.23 
Distributors of drug products have also contributed to the overall problem of drug 
shortage in terms of the lack of providing information to health facilities regarding drug 
shortages in a timely manner. Being unaware of existing drug shortage makes the 
development of a strategy for managing drugs in short supply hard to achieve. In 
addition, hospitals in rural areas are further challenged by the unavailability of 
distribution centers near them and other hospitals from which they could borrow a drug 
product. Therefore, it is extremely important for health professionals to have access to 
reliable information resources in order to be able to successfully manage drug 
shortages.24  
1.1.4 Information Resources for Managing Drug Shortages 
Managing drug shortages has become a routine practice within health care 
facilities where health care professionals dedicate personnel time and resources to 
identify, track, and resolve existing drug shortages. This process involves obtaining the 
necessary information regarding reasons for product’s unavailability, time period for the 
product’s shortage (i.e. when the product’s supply will be available), alternative supply 
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resource, alternative therapies, and cost related to alternative suppliers or therapies.25 
Gathering information and maintaining an excellent network of communication are 
crucial in minimizing the impact of a drug shortage. The main information resources 
providing assistance with current drug shortages are the Food and Drug Administration, 
the American Society of Health-System Pharmacists, and the Centers for Disease Control 
and Prevention (CDC).26 The FDA’s web site 
(www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm) provides a list of current 
drug shortages, reasons for drug shortages, availability and estimated shortage duration, 
updates on resolved shortages, and information about drugs that are going to be 
discontinued. The site does not present any clinical information with regard to alternative 
therapies and possible implications for patient care that could help health professionals 
deal with a particular shortage.27, 28 In addition, the FDA’s web site instructs users on 
how to report a drug shortage or supply issue, sign up for drug shortage e-mail 
notifications, and contact manufacturers.29 ASHP in collaboration with UUDIS and 
Novation, LLC have created Drug Shortage Bulletins available on ASHP web site 
(www.ashp.org/shortages) in which information is provided detailing current drug 
shortages, reasons for drug shortages, estimated re-supply dates, implications for patient 
care, safety issues, and alternative agents.30,31 The CDC’s web site 
(www.cdc.gov/vaccines/vac-gen/shortages/default.htm) informs about existing vaccine 
shortages and provides recommendations regarding modifications of immunization 
schedules.32 In addition, the FDA’s Center for Biological Evaluation Research (CBER) 
web site 
(www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/default.htm) 
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provides information about current blood, vaccines and biologics shortages.33 Moreover, 
ASHP recommends contacting manufacturers and distributers in order to get information 
on causes and duration of current drug shortages.34 
In an online survey conducted by ASHP in 2010, 1322 members of ASHP were 
asked to rate the quality of various sources of information currently available to health 
professionals. In particular, they were asked to rate the usefulness of ASHP drug shortage 
web site, FDA drug shortage web site, wholesalers and group purchasing organizations, 
and direct communication with manufacturers using a 5-point Likert scale. Overall, the 
results showed that 70% of the respondents rated the information available on all 
specified sources as less than good.35 Table 1.1 shows participants’ ratings of the 
usefulness of selected information sources. 
 
Table 1.1: Respondents’ Ratings of Existing Information Sources on Drug Shortages 
Rated 
Characteristics 
ASHP 
Web Site 
FDA Web 
Site 
Wholesaler 
Web Site or 
Communication 
 
GPO Web Site 
or 
Communication 
 
Direct 
Communication 
With 
Manufacturer 
 
Timeliness 
 
3.93 3.40 3.38 3.42 3.02 
Reason for and 
duration of 
shortage 
provided  
3.80 3.23 2.66 3.23 2.78 
Suggested 
alternatives 
provided  
 
3.97 2.74 1.81 3.04 1.92 
 
ASHP = American Society of Health-System Pharmacists; GPO = group-purchasing organization. 
aMean rating, based on a 5-point Likert scale, where 1 = very poor, 2 = poor, 3 = neutral, 4 = good, and 
5 = very good.  
Source: Kaakeh R, Sweet BV, Reilly C, Bush C, DeLoach S, Higgins B, et al. Impact of drug shortages 
on U.S. health systems. Am J Health Syst Pharm. 2011; 68: e13-17. 
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1.2 LITERATURE REVIEW 
 
This section will cover causes of drug shortages, impact of drug shortages on 
patient care, and grey market activities associated with drug shortages. 
1.2.1 Causes of Drug Shortages 
 Drug shortages exist for variety of reasons. Quoting FDA, the primary cause of 
shortages is production shutdowns because of manufacturing problems, such as 
contamination and metal particles that get into medicine.36 Yet, according to UUDIS the 
reason for 47% of the drug shortages tracked in 2010, is unknown. 37 Figure 1.6 illustrates 
the reasons for drug shortages in 2010. 
 However, there are other factors throughout the supply chain that are equally 
important in their contribution to the drug shortage crisis. These factors include 
interruptions in the supply of raw materials, manufacturing and regulatory issues, 
business decisions, changes in clinical practice, industry consolidation, and natural 
disasters.38,39 Figure 1.7 depicts the parties involved in the drug supply distribution chain. 
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Figure 1.6: Reasons for Drug Shortages, 2010 
Source: American Society of Health-System Pharmacists. Drug Shortages Summit Report. Available at: 
http://www.ashp.org/drugshortages/summitreport. Accessed June 20, 2012. 
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Figure 1.7: Drug Supply Chain 
Source: Food and Drug Administration. A Drug Supply Chain Example. From Supplier to Patient. 
Available at: www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm277626.htm. Accessed December 12, 
2011. 
 
1.2.1.1 Interruptions in the Supply of Raw Materials 
 Interruptions in the supply of raw or bulk materials often lead to a drug shortage 
particularly in situations when the primary or sole supplier of raw materials experiences 
delays or discontinues production and thus affecting all manufacturers of a particular 
drug product.40 In fact, drug manufacturers are increasingly relying on a global supply 
chain for the raw materials.41 It has been estimated that 80% of the raw materials used in 
the manufacture of drug products in the United States are imported from other 
countries.42 Armed conflicts, trade disruptions, animal diseases, environmental 
conditions, or degradation of raw materials during harvesting, storage, or transportation, 
are all factors that may contribute to the disruption of the supply of raw materials.43 
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1.2.1.2 Manufacturing and Regulatory Issues 
 Once the primary or sole manufacturer of a drug product experiences 
noncompliance with current good manufacturing practices (cGMP) a drug shortage could 
result as a consequence of halts or delays in drug production.44 The main factors that 
might contribute to regulatory issues within a drug manufacturing company include 
antiquated manufacturing equipment, a shift of resources from maintenance of equipment 
and facilities to research and development, loss of manufacturer personnel, cGMP-related 
problems with subcontractors who supply products, and limited FDA resources for timely 
inspections of manufacturing sites.45 In addition, the resolution of such issues may 
require inspection for recertification, issuance of an injunction against the manufacturer, 
or seizure of products. Moreover, in some instances a manufacturer might decide to close 
a specific facility and thus contribute to unintended drug shortages.46 
1.2.1.3 Business Decisions 
 Availability of generic products, market size, patent expiration, drug-approval 
status, regulatory compliance requirements, and anticipated clinical demand are all 
factors that influence drug manufacturers’ business decisions. Yet, in many instances the 
main factor that influences a manufacturer’s decision to discontinue production of a 
specific drug product is the insufficient financial return or the high cost to correct 
manufacturing issues. This could lead to an unanticipated serious drug shortage 
especially if the manufacturer is a sole-source.47 For example, a manufacturer of 
diphtheria and tetanus toxoids and acellular pertussis vaccine announced in 2000 the 
discontinuation of its products due to low revenues resulting in a vaccine shortage.48 
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1.2.1.4 Changes in Clinical Practice 
 Changes in clinical practice, such as a new indication of an existing drug product, 
new therapeutic guidelines, or disease outbreak, could lead to an unexpected increase in 
the demand for a specific drug product, which exceeds production capacity. One such 
drug shortage occurred, in 2006, when CDC changed its guidelines for pediatric flu 
vaccine to include children 6 to 59 months of age resulting in an increased demand for 
the only product approved by FDA in children 6-23 months of age.49 
1.2.1.5 Industry Consolidation 
 Industry consolidation, in the form of manufacturer mergers or acquisition could 
result in discontinuation or delayed availability of drug products. In many instances 
manufacturer mergers narrow the focus of production lines or result in single-source 
products, especially when two companies producing similar product merge. As a result 
there is fewer number of manufacturers of a particular drug product, which in turn makes 
the product supplies more vulnerable to any disruptions in the supply chain.50 
1.2.1.6 Natural Disasters 
 Natural disasters, such as fires, hurricanes, tornadoes, and floods, could have 
devastating effects on drug product availability. Moreover, a long-term drug shortage 
could occur if a manufacturing facility has been damaged especially in instances of sole-
source product. An example is the damage caused by hurricane George in 1998 to 
manufacturing facilities in Puerto Rico resulting in several drug product shortages.51 
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1.2.2 The Impact of Drug Shortages  
 The most important implications of drug shortage include the hampering of 
patient care, increased drug costs, and an increased burden on health professionals in 
managing drug shortages. With regard to patient care, drug shortages may adversely 
affect patient’s drug therapy, compromise or delay medical treatment procedures, or 
result in medication errors or adverse patient outcomes. In addition, drug shortages have 
financial and emotional effects. Costly alternative medications might be needed to 
continue patient treatments, and health care professionals might need a significant 
amount of time and resources to manage shortages. Patients and professionals might 
become frustrated, angry, and develop mistrust. Professional relationships might also 
become strained.52 A national survey of more than 1,800 health care practitioners 
conducted by the Institute for Safe Medication Practices (ISMP), in the period between 
July and September 2010, revealed that 64% of the respondents were concerned with risk 
of adverse patient outcomes as a result of drug shortages, 70% expressed anger toward 
pharmacists, nurses and hospitals in response to a drug shortage, 80% indicated facing 
difficulties when trying to obtain a suitable alternative, and 35% reported a near miss due 
to a drug shortage.53 ISMP defines near miss as a situation in which an error has occurred 
yet it was captured by a health professional before it could reach and harm the patient.54 
Another survey of 311 pharmacy experts performed by Premier Healthcare Alliance in 
the period between July and December 2010 reported similar results. Of the surveyed 
respondents, 89% experienced shortages that may have caused a medication safety issue 
or error in patient care, 80% experienced shortages that resulted in a delay or cancellation 
of a patient care intervention, 98% experienced shortages that resulted in an increase in 
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costs.55 One of the first national surveys conducted across acute care hospitals by ASHP 
in 2004 revealed that almost all pharmacy directors surveyed agreed that drugs shortages 
changed practice and compromised patient care. In addition, it was found that hospital 
pharmacy personnel spent a considerable amount of time managing drug shortages and 
the acquisition cost of pharmaceuticals increased by over $99 million annually as a 
consequence of drug shortages.56 In 2011, ASHP performed another national survey 
looking at the impact of drug shortages on U.S. health systems, and it was found that 
pharmacists and pharmacy technicians devoted more time managing drug shortages than 
other healthcare professionals, like physicians and nurses, and that the labor cost 
associated with managing drug shortages was estimated to be $216 million annually. In 
addition, it was reported that there was a significant association between the number of 
drug shortages experienced and the hospital size as well as  between the time spent 
managing drug shortages and the size of the facility, and the number of shortages 
experienced.57 The American Hospital Association (AHA) released the results of its 
survey of 820 hospitals in July 2011 revealing that 82% of the hospitals delayed patient 
treatment, more than half (63%) were not always able to provide the recommended 
treatment to the patients, and 92% reported increased drug costs.58  
1.2.3 Grey Market 
The drug shortages issue is further complicated by the practices of grey market 
vendors who take advantage of the situation. The grey market vendors are sellers who 
might not be licensed or authorized secondary distributors. They buy scarce drugs from 
small regional wholesalers, pharmacies or other sources and then market them to 
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hospitals at inflated prices.59 These distributors market drug products in short supply to 
hospitals, specialty health systems, home care agencies, and physician practices, at 
substantially inflated prices. The main concerns of these activities come from the 
inability to determine the product’s pedigree or ensure the reliability of the product’s 
source, proper handling and storage throughout the chain of ownership.60 
For example, at Christus Santa Rosa Health Care, Texas, Cytarabine, an injectable 
cancer drug for treatment of leukemia costs on average $15.76 for a 2-gm vial, but with 
the drug in short supply, suppliers have offered 17 vials for $995 each, a markup of 
6213%. The same problem exists at many healthcare systems across Texas. Baptist 
Health System is spending $125,000 per month extra in premiums for Cytarabine and 
other drugs in short supply.61 Texas Medical Center hospital pharmacists managed the 
crisis by getting rare FDA exemptions for the importation of drugs from Europe.62 A 
2011 survey, conducted by ISMP, examined grey market activities associated with drug 
shortages among hospital purchasing agents and pharmacists.  Of 549 respondents, 56% 
reported receiving daily solicitations from grey market vendors and 52% reported 
purchasing drugs from grey market vendors in the last two years.  Many respondents 
provided examples of inflated prices, including Propofol that was marked up by over 
1567%. 63 Similar results were reported by Premier Healthcare Alliance in their survey of 
pharmacists regarding the incidence of grey market offers. They reported 1,745 examples 
of grey market offers over a two-week period among 42 acute care hospitals with an 
average markup of 650%.64 
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1.2.4. Summary of Literature Review 
Hospitals have been combating the increasing number of drug shortages since 
2001.65 The main factors contributing to the drug shortage crisis include interruptions in 
the supply of raw materials, manufacturing and regulatory issues, business decisions, 
changes in clinical practice, industry consolidation, and natural disaseters.66,67 Drug 
shortages have had a significant impact on patient care. The most important implications 
of drug shortage include hampering patient care, increased drugs’ costs, and an increased 
burden on health professionals in managing drug shortages and obtaining needed drug 
products. With regard to patient care, drug shortages might adversely affect drug therapy, 
compromise or delay medical treatment procedures, fail to treat diseases, result in 
medication errors and adverse patient outcomes. In addition, drug shortages have 
financial and emotional effects on both health care practitioners and patients. Costly 
alternative medications might be needed to continue patient’s treatments, and health care 
professionals might need significant amount of time and resources to manage shortages. 
Patients as well as professionals may become frustrated, angry, and develop mistrust.68 
The drug shortage issue is further complicated by the practices of “grey market” vendors 
who take advantage of the shortage situation and thus significantly contribute to the 
difficulties in obtaining drugs in short supply.69 These vendors promote drug products in 
short supply to health care facilities at dearly inflated prices. Health professionals are 
mainly concerned about the quality of the drug products marketed by grey market 
vendors because product’s pedigree, source, handling, and storage are difficult to be 
determined.70 
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This study explores the incidence and impact of drug shortages across Texas 
Acute Care Hospitals. The study determines if the number of drug shortages experienced 
by a hospital is related to the size in terms of number of beds of a hospital, its type, 
location, and medication budget. In addition, the study finds out whether hospital 
pharmacy personnel dedicate more time in managing drug shortages as the number of 
drug in short supply increases. Furthermore, the study will examine if hospital pharmacy 
personnel believe grey market vendors contribute toward the drug shortages crises. 
Previous study has reported a significant association between the number of drug 
shortages experienced and the hospital size as well as  between the time spent managing 
drug shortages and the size of the facility, and the number of shortages experienced.71 
The project gives an in depth picture of the existing drug shortage problem within 
Texas acute care hospitals and will contribute to further understanding of the nationwide 
problem of drug shortages and its implications. 
1.2.5 Objectives 
The purpose of this study is to explore the incidence and impact of drug shortages across 
Texas Non-Government Acute Care Hospitals. The specific objectives of this study are as 
follows: 
1. To assess the proportion of Texas Non-Government Acute Care Hospitals 
experiencing a drug shortage and the number of shortages experienced in the last 
month (April, 2013); 
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2. To determine the percentage of Texas Non-Government Acute Care Hospitals 
affected by each of the 15 most recent drug shortages as of April 2013 (according 
to ASHP) for the last month; 
3. To estimate the average number of hours per week spent by hospital pharmacy 
staff managing drug shortages and the activities associated with managing drug 
shortages; 
4. To examine whether additional hospital pharmacy personnel were hired as a 
result of increased workload due to drug shortages; 
5. To determine whether hospital pharmacy personnel were shifted from patient 
care activities toward managing drug shortages and which activities have been 
affected the most; 
6. To describe the various supply and informational resources used to obtain 
drugs in short supply and information on drug shortages, as well as respondents’ 
opinions with regard to the most common causes of drug shortages; 
7. To assess the number of acute care hospitals contacted by grey market vendors 
in the last month (April, 2013), frequency and mode of contact, concerns and 
opinions of hospital pharmacy personnel regarding grey market activities 
associated with current drug shortages; 
1.2.6 Hypotheses 
Based on the study objectives the following hypotheses will be tested: 
HA1: There is an association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and facility size in terms of number of beds.  
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H02: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and  facility type (Chain and Non-Chain 
hospitals). 
 H03: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and hospital inpatient medication budget. 
 H04: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and facility location (Rural/Semi-Urban, 
Small/Medium Metropolitan and Large Metropolitan). 
HA5: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and facility size in terms of number 
of beds. 
 HA6: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and number of drug shortages 
experienced by the health system in the last month (April, 2013). 
HA7: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and number of pharmacist FTEs. 
HA8: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and number of pharmacy technicians 
FTEs. 
H09: There is no association between the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors across facility sizes in terms of number of beds. 
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H010: There is no association between the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors by number of shortages experienced by the health 
system in the last month (April, 2013).  
H011: There is no association between the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors by facility type (Chain and Non-Chain hospitals). 
 H012: There is no association between the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors by and facility location (Rural/Semi-Urban, 
Small/Medium Metropolitan and Large Metropolitan).    
H013: There is no difference in the mean opinion score of hospital pharmacy personnel 
whether grey market vendors contribute toward the drug shortages crises by buying 
whatever supplies they can find on the market controlling for position within the facility 
(Managers and Staff) and number of drug shortages experienced by the health system in 
the last month (April, 2013). 
H014: There is no difference in the mean perception score of hospital pharmacy personnel 
in regard to grey market vendors’ practice of selling drugs in short supply at inflated 
prices by their position within the facility (Managers and Staff) and number of drug 
shortages experienced by the health system in the last month (April, 2013). 
H015: There is no difference in the mean opinion score of hospital pharmacy personnel 
toward elimination of the practice of buying drugs in short supply from grey market 
vendors by their position within the facility (Managers and Staff) and number of drug 
shortages experienced by the health system in the last month (April, 2013). 
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Chapter Two: Methodology 
 
This chapter describes the methods used in conducting the study. It details the 
instrument, instrument development, selection of study respondents, survey 
administration, data collection, and analyses.  The study was divided into two phases. 
The first phase included development of the survey questionnaire, selection of survey 
participants, completion of IRB approval, and pretest of the questionnaire. The second 
phase involved survey administration, data collection, and data analysis. 
The study design employed a self-reported questionnaire of hospital pharmacy 
directors of non-government acute care hospitals located in Texas. A total of 321 acute 
non-government care hospitals were identified via the Texas Department of State Health 
Services (DSHS) directory and 321 were mailed a packet, which contained a cover letter, 
questionnaire, and return envelope.   
2.1 PHASE ONE 
2.1.1 Survey Instrument 
A survey questionnaire was comprised of 26 items (Appendix 1). The survey 
questionnaire was divided into three sections and had 18 close-ended items, 1 open-ended 
and 7 partially close-ended questions. 
The following presents descriptions of the items by section and Table 2.1 presents 
the operational definitions and measurement levels of each questionnaire item (variable), 
as well as each variable location in the survey instrument. 
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  The first section explored hospital pharmacy personnel experience with regard to 
drug shortages. It consisted of closed-ended and partially close-ended questions with the 
objective of collecting the following information from respondents: 
1. Number of drug shortages experienced in the last month (April, 2013)  
(question 1); 
2. Perception of the degree of the drug shortage problem (question 2); 
3. Drug shortages experienced for specified medicines (question 3); 
4. Activities in managing drug shortages (question 4); 
5. Number of hours per week spent managing drug shortages (question 5); 
6. Whether or not additional personnel were hired as a result of increased 
workload due to drug shortages (question 6 and 7); 
7. The degree to which patients’ care activities were affected as a result of shifting 
hospital staff personnel toward managing drug shortages (question 8 and 9); 
8. Drug supply sources commonly used for obtaining drugs in short supply 
(question 10); 
9. Information resources commonly used to obtain additional information on 
drugs in short supply (question 11); and 
10. Ranking of the top three reasons for drug shortages (question 12). 
  
The second section examined respondents’ practice and their opinions in regard to 
grey market vendor activities associated with drug shortages. For the purpose of getting 
the same perspective, “grey market” was defined as a supply channel that is unofficial, 
unauthorized or unintended by the original manufacturer for distribution of medicines. 
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This section contained 12 questions including an open-ended question, closed-ended and 
partially closed-ended questions with the objective of collecting the following 
information from respondents: 
1. Number of times contacted by grey market vendors in the last month (question 
13); 
2. Number of times solicited by grey market vendors to buy drug products 
(question 14); 
3. Number of times grey market vendors solicited the hospitals to purchase 
products from the hospital (question 15); 
4. The most widely used methods hospital pharmacists hear about products 
available from the grey market vendors (question 16); 
5. Collect hospital pharmacists perceptions as to the main concerns regarding the 
purchasing of drug products from grey market vendors (question 17); and 
6. Hospital pharmacy personnel perceptions with regard to grey market vendors’ 
activities associated with drug shortages (question 18). 
 
The third section used eight questions to gather information about respondents’ 
demographics and practice setting characteristics. The following information was 
collected using closed-ended and partially closed-ended questions: 
1. Type of facility (question 19); 
2. Position within facility (question 20); 
3. Whether or not the person who completed the questionnaire was licensed 
pharmacist (question 21); 
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4. Number of pharmacist full-time-equivalents at the facility (question 22); 
5. Number of pharmacy technician full-time-equivalents (question 23); 
6. Facility size in terms of number of beds (question 24); 
7. Inpatient medication budget (question 25); and 
8. Facility geographic location (question 26).
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Table 2.1: Operational Definitions of Variables Contained in the Survey Instrument 
Variable Name 
 
Operational Definition Measurement level/ Variable labels Survey 
Section 
(Number) 
Number Drug 
Shortages 
Number of drug shortages each hospital 
experienced in the last month 
 
Ordinal: 0 = None, 1= 1-2, 3= 3-4, 4=5-6, 5=9-10, 
6= ≥ 11 
I (1) 
Degree of 
Problem 
Degree of the of drug shortages’ problem 
regarding each hospital setting  
 
Ordinal: 1= No problem, 2= Not much of a problem,  
3 = Some kind of a problem 
I (2) 
Drug Shortages List of 15 drug shortages  
 
Dichotomous: 1= No, 2= Yes I (3) 
Activities  Activities associated with drug shortages 
 
Dichotomous: 1= No, 2= Yes I (4) 
Week hours Number of hours per week (h/w) hospital 
pharmacy staff spend managing drug shortages 
Ordinal: 1= 1-3 h/w, 2= 4-6 h/w, 3= 7-9 h/w,  
4= 10-12 h/w, 5= 13-15 h/w, 6= ≥ 16 h/w  
I (5) 
Additional Staff Additional staff hired as a result of increased 
workload due to drug shortages 
Dichotomous: 1= No, 2= Yes I (6) 
Number of 
additional staff 
Number of additional staff hired as a result of 
increased workload due to drug shortages 
Interval I (7) 
Personnel 
Shifted  
Hospital pharmacy personnel shifted from 
patients’ care activities toward managing drug 
shortages 
Dichotomous: 1= No, 2= Yes I (8) 
Activities 
affected 
Activities that have been affected as a result of 
shifting hospital pharmacy personnel toward 
managing drug shortages 
Categorical: 0 = Not Selected, 1= Highly Affected, 
2= Some What Affected, 3= Not Affected 
I (9) 
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Table 2.1: Operational Definitions of Variables Contained in the Survey Instrument (continued) 
Variable Name 
 
Operational Definition Measurement level/ Variable labels Survey 
Section 
(Number) 
Supply 
Resources  
Resources commonly used while obtaining 
drugs in short supply 
Categorical: 0 = Not Selected,  
1= Most Widely Used, 2= Second Most Widely 
Used, 3= Third Most Widely Used 
I (10) 
Information 
Resources 
Information resources used to obtain 
information on drugs in short supply 
Dichotomous: 1= No, 2= Yes I (11) 
Reasons  Reasons of drug shortages Categorical: 0 = Not Selected, 1= Most Common 
Reason, 2= Second Most Common Reason,  
3= Third Most Common Reason 
I (12) 
Grey Market 
Contact  
Hospital pharmacy staff personnel contacted 
by a grey market vendor 
 
Categorical: 1= No, 2= Yes, 3= Don’t know II (13) 
Number of grey 
market contact  
Number of times contacted by grey market 
vendors 
 
Interval  II (13) 
Incidence of 
grey market to 
sell  
Incidence of grey market vendors contacts with 
hospital staff personnel to sell their products  
Categorical: 0 = None 1= Monthly, 2= Less than 
monthly, 3= Weekly, 4= Daily 
II (14) 
Incidence of 
grey market to 
buy 
Incidence of grey market vendors contacts with 
hospital staff personnel to buy products  
Categorical: 0 = None 1= Monthly, 2= Less than 
monthly, 3= Weekly, 4= Daily 
II (15) 
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Table 2.1: Operational Definitions of Variables Contained in the Survey Instrument (continued) 
Variable Name 
 
Operational Definition Measurement level/ Variable labels Survey 
Section 
(Number) 
Contact 
methods 
Methods by which hospital pharmacy staff 
personnel hear about products available from 
the gray market vendors 
 
Categorical: 0 = Not Selected, 1= Most Widely 
Used, 2= Second Most Widely Used,  
3= Third Most Widely Used 
II (16) 
Concerns Concerns regarding purchasing products from 
grey market vendors 
  
Dichotomous: 1= No, 2= Yes II (17) 
Grey market 
Likelihood  
Grey market vendors’ likelihood to contact 
facility when drug shortage exists 
Interval (Likert Scale): 1= Strongly Disagree,  
2= Disagree, 3= Neutral, 4= Agree,  
5= Strongly Agree 
II (18a) 
Grey Market 
Ability 
Grey market vendors’ ability to identify and 
obtain drugs in short supply 
Interval (Likert Scale): 1= Strongly Disagree,  
2= Disagree, 3= Neutral, 4= Agree,  
5= Strongly Agree 
II (18b) 
Grey Market 
Contribution  
Grey market vendors’ contribution to the drug 
shortage crises 
Interval (Likert Scale): 1= Strongly Disagree,  
2= Disagree, 3= Neutral, 4= Agree,  
5= Strongly Agree 
II (18c) 
Grey Market 
Contribution  
Grey market vendors’ contribution to the drug 
shortage crises 
Interval (Likert Scale): 1= Strongly Disagree,  
2= Disagree, 3= Neutral, 4= Agree,  
5= Strongly Agree 
II (18c) 
Grey Market 
Price 
Grey market vendors sell drugs in short supply 
at inflated prices 
Interval (Likert Scale): 1= Strongly Disagree,  
2= Disagree, 3= Neutral, 4= Agree,  
5= Strongly Agree 
II (18d) 
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Table 2.1: Operational Definitions of Variables Contained in the Survey Instrument (continued) 
Variable Name 
 
Operational Definition Measurement level/ Variable labels Survey 
Section 
(Number) 
Grey Market 
Markups 
Grey market vendors offer drugs in short 
supply needed to treat critically ill patients at 
largest markups 
 
Interval (Likert-Like Scale): 1= Strongly Disagree, 
2= Disagree, 3= Neutral, 4= Agree, 5= Strongly 
Agree 
II (18e) 
Grey Market 
Source 
Grey market vendors as the only source 
available for obtaining a drug in shortage  
 
Interval (Likert-Like Scale): 1= Strongly Disagree, 
2= Disagree, 3= Neutral, 4= Agree, 5= Strongly 
Agree 
II (18f) 
Grey Market 
Elimination 
Eliminating the practice of buying products 
from grey market vendors  
 
Interval (Likert-Like Scale): 1= Strongly Disagree, 
2= Disagree, 3= Neutral, 4= Agree, 5= Strongly 
Agree  
II (18g) 
Facility type Hospital type Categorical: 1= Community Hospital, 2= Chain 
Hospital, 3= Children’s Hospital, 4= Health Care 
Group Hospital, 5=Health Care System Hospital,  
6= University Hospital, 7= Other (please, specify) 
  
III (19) 
Position Pharmacist position within the hospital Categorical: 1= Director of pharmacy, 2= Pharmacy 
manager, 3= Pharmaceutical purchasing agent,  
4= Staff pharmacist, 5= Pharmacy technician,  
6= Pharmacy clerk, 7= Other (please, specify) 
 
III (20) 
License  Pharmacist license  
 
Dichotomous: 1= No, 2= Yes III (21) 
Pharmacist 
(FTEs) 
Number of Pharmacist Full Time Equivalents 
(FTEs) 
 
Categorical: 1= ≤ 10, 2= 11- 25, 3= 26- 50, 4= > 50 III (22) 
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Table 2.1: Operational Definitions of Variables Contained in the Survey Instrument (continued) 
Variable Name 
 
Operational Definition Measurement level/ Variable labels Survey 
Section 
(Number) 
Pharmacy 
Technician 
(FTEs) 
Number of Pharmacist Technician Full Time 
Equivalents (FTEs) 
Categorical: 1= ≤ 10, 2= 11- 25, 3= 26- 50, 4= > 50 III (23) 
Hospital Size Hospital size in terms of number of beds Categorical: 1= < 100, 2= 100 – 150 beds, 3= 151 – 
250 beds, 4= 251 - 350 beds, 5= 351 – 450 beds,  
6= > 451 
 
III (24) 
Budget Hospital inpatient medication budget per year Categorical: 1= <  $1.5 million, 2= $1.5-5.0 million, 
3= $5.0-10 million, 4= > $10 million 
 
III (25) 
Hospital 
Location 
Hospital location Categorical: 6= Large Metropolitan, 5= Medium 
Metropolitan, 4=Small Metropolitan,  
3= Semi- Urban, 2= Semi- Rural, 1= Rural 
 
III (26) 
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2.1.2 Institutional Review Board Approval 
This study received an expedited approval from the University of Texas 
Institutional Review Board (IRB Protocol # 2012-07-0010) on April 2, 2013. 
2.1.3 Sample Selection 
The study population of interest was Texas non-government acute care hospitals, 
identified through the Texas Hospital List for 2012, which is available on the Texas 
Department of State Health Services (DSHS) website 
(http://wwwprod.dshs.state.tx.us/default.shtm). Texas DSHS is a state agency, which 
provides state-operated health care services, including hospitals, health centers, and 
health agencies. The Center for Health Statistics, within the Texas DSHS, conducts 
annual survey of Texas hospitals in collaboration with the American Hospital Association 
and releases a comprehensive list of all Texas hospitals each year. The 2012 Texas 
Hospital List had an alphabetical listing of Texas hospitals and the city where each 
hospital is located. It also had the complete hospital name, address, county, zip code, 
number of beds, and type of ownership. All non-federal government acute care hospitals, 
irrespective of their ownership (i.e., for-profit, not-for-profit), with 50 or greater beds 
were selected and surveyed. A total sample of 321 hospitals was selected from the Texas 
Hospital List for 2012 that included every non-government acute care hospital with 50 or 
greater beds. 
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2.1.4 Pretest 
 The survey questionnaire was pretested on a convenience sample of seven Texas 
hospital pharmacists working at non-government acute care hospitals. The survey 
questionnaire, a cover letter and a questionnaire evaluation form were sent electronically 
by email to selected hospital pharmacists. The hospital pharmacists were asked to provide 
feedback on the clarity and completeness of the questionnaire by identifying unclear or 
confusing items and offering suggestions. In addition, the pretest individuals were asked 
to record the time needed to complete the survey instrument.  
 After receipt of all pretest evaluation forms and based on reviewers’ 
recommendations some items were reworded and two new items were added to the 
survey instrument. For example, the list representing recent drug shortages (Question 3) 
was updated in order to reflect the current drug shortages as recommended by the 
reviewers. In addition, the answer choices in Question 4 “Preparing written 
communications for health care providers” and “Communicating information to other 
health care providers” were viewed as repetitive and therefore the first answer choice 
was removed, yet a new answer choice was added “Communicating drug shortage 
information to hospital administration” to better reflect current practices within hospitals. 
A new question (Question 9) was added to capture the patient care activities that have 
been affected as a result of shifting hospital pharmacy personnel toward managing drug 
shortages. Furthermore, a new question (Question 12) was included to assess hospital 
pharmacy staff considerations in regard to most common reasons for the current drug 
shortages. The reviewers reported that the time needed to complete the survey was 
between 10 and 15 minutes. 
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2.2 PHASE TWO 
2.2.1 Survey Administration 
 The questionnaire and a cover letter (see Appendix I and Appendix II) were 
mailed to the pharmacy directors for each of the 321 selected hospitals. The cover letter 
provided explanation of the purpose of the study, voluntary participation, respondents’ 
confidentiality, security, anonymity of responses, IRB approval, and approximates time 
for completion of the questionnaire. It was stated that completing and returning the 
questionnaire would serve as consent for study participation. In addition, the cover letter 
included contact information of the Office of Research Support and the researchers 
involved in the study so that participants could direct any questions about the research. 
Responders were offered an aggregate summary of the study as an incentive to 
participate. A follow-up reminder mail was not sent due to budget constraints.  
2.2.2 Data Collection 
 The data were collected in the period between May 09, 2013 and June 10, 2013, a 
one-month time period. 
2.2.3 Data Analysis 
 Data from the questionnaire were entered into the Predictive Analytics Software 
(PASW)® version 18.0 for analysis. The data were cleaned and descriptive analysis was 
performed on all variables.  
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2.2.3.1 Descriptive Analysis  
 Descriptive analysis (means, standard deviations, frequency distribution) will be 
reported for all variables derived from the instrument. Means will be reported for 
continuous variables such as ‘number of times hospital pharmacy personnel got contacted 
by grey market vendors’ (item 13), ‘perceptions regarding grey market vendors 
contribution toward the drug shortages crises’ (item 18b), ‘perceptions toward grey 
market vendors practice of selling drugs in short supply at inflated prices’ (item 18d), 
and ‘perceptions toward elimination of the practice of buying drugs in short supply from 
grey market vendors’ (item 18g).     
Counts and percentages will be reported for categorical variables such as  
‘number of drug shortages experienced’ (item 1), ‘number of hours per week managing 
drug shortages’ (item 5), ‘facility type’ (item 19), ‘position within facility’ (item 20), 
‘pharmacy licensure’ (item 21), ‘number of pharmacist FTEs’ (item 22), ‘number of 
pharmacy technician FTEs’ (item 23), ‘facility size’ (item 24), ‘inpatient medication 
budget’ (item 25), and ‘facility location’ (item 26).  
2.2.3.2 Independent Variables 
The independent variables for this project are ‘facility type’ (item 19), ‘position 
within facility’ (item 20), ‘pharmacy licensure’ (item 21), ‘number of pharmacist FTEs’ 
(item 22), ‘number of pharmacy technician FTEs’ (item 23), ‘facility size’ (item 24), 
‘inpatient medication budget’ (item 25), and ‘facility location’ (item 26).  
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2.2.3.3 Dependent Variables 
Based on the study objectives the dependent variables are: ‘ number of drug 
shortages experienced’ (item 1), ‘number of hours per week managing drug shortages’ 
(item 5), ‘number of additional staff hired as a result of increased workload due to drug 
shortages’ (item 7), ‘number of times hospital pharmacy personnel got contacted by grey 
market vendors’ (item 13), and perceptions toward whether grey market vendors 
‘contribute toward the drug shortages crises’ (item 18b), ‘sell drugs in short supply at 
inflated prices’ (item 18d), and ‘practice of selling drugs in short supply need to be 
eliminated’ (item 18g). 
2.2.3.4 Hypotheses Testing 
 All statistical analysis will be performed using Predictive Analytics Software ® 
(PASW®) Statistics 18.  An a priory significance level of p  0.05 will be used for all 
statistical tests. Table 2.2 summarizes the study hypothesis, variables, and statistical tests 
employed.  
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Table 2.2: Summary of Hypothesis, Variables and Statistical Tests 
Hypothesis Dependent Variable (DV) Independent Variable (IV) Statistical Test 
HA1 Number of drug shortages experienced by a health 
system: Categorical 
Facility size: Categorical Chi-square 
 
H02 Number of drug shortages experienced by a health 
system: Categorical 
Facility type: Categorical Chi-square 
 
H03 Number of drug shortages experienced by a health 
system: Categorical 
Inpatient medication  budget: 
Categorical        
Chi-square 
 
H04 Number of drug shortages experienced by a health 
system: Categorical 
Location: Categorical Chi-square 
HA5 Number of hours spent per week by hospital 
pharmacy personnel when managing drug 
shortages: Categorical 
Facility size: Categorical 
 
Chi-square 
 
HA6 Number of hours spent per week by hospital 
pharmacy personnel when managing drug 
shortages: Categorical 
Number of drug shortages: 
Categorical 
 
Chi-square 
 
HA7 Number of hours spent per week by hospital 
pharmacy personnel when managing drug 
shortages: Categorical 
Number of pharmacist FTEs: 
Categorical 
 
Chi-square 
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Table 2.2: Summary of Hypothesis, Variables and Statistical Tests (Continued) 
Hypothesis Dependent Variable (DV) Independent Variable (IV) Statistical Test 
HA8 Number of hours spent per week by hospital 
pharmacy personnel when managing drug 
shortages: Categorical 
Number of pharmacy technicians 
FTEs: Categorical 
 
Chi-square 
 
H09 Number of times hospital pharmacy personnel were 
contacted by grey market vendors: Categorical 
 
Facility size: Categorical Chi-square 
 
H010 Number of times hospital pharmacy personnel were 
contacted by grey market vendors: Categorical 
Number of drug shortages: 
Categorical 
 
Chi-square 
 
H011 Number of times hospital pharmacy personnel were 
contacted by grey market vendors: Categorical 
 
Facility type: Categorical  Chi-square 
 
H012 Number of times hospital pharmacy personnel were 
contacted by grey market vendors: Categorical 
Location: Categorical Chi-square 
 
H013 Grey market vendors contribute toward the drug 
shortages crises by buying whatever supplies they 
can find on the market: Interval 
Position (IV1): Categorical 
Number of drug shortages  (IV2): 
Categorical 
 
Two sample T-test 
One-way ANOVA 
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Table 2.2: Summary of Hypothesis, Variables and Statistical Tests (Continued) 
Hypothesis Dependent Variable (DV) Independent Variable (IV) Statistical Test 
H014 
 
 
 
 
Grey market vendors’ practice of selling drugs in 
short supply at inflated prices: Interval 
 
 
 
 
 
 
Position (IV1): Categorical 
Number of drug shortages  (IV2): 
Categorical 
 
 
Two sample T-test 
One-way ANOVA 
 
H015 Elimination of the practice of buying drugs in short 
supply from grey market vendors: Interval 
 
Position (IV1): Categorical 
Number of drug shortages (IV2): 
Categorical 
Two sample T-test 
One-way ANOVA 
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Chapter Three: Results 
 
 This chapter presents the results of the survey data analysis. In particular, it 
details respondents’ demographic and practice setting characteristics, in addition to 
descriptive analysis and hypothesis testing.  
3.1 SURVEY RESPONSE RATE 
 A total of 321 self-administered mail surveys and cover letters were sent to 
hospital directors of non-government acute care hospitals in the State of Texas. Data 
collection period was set beginning on May 09, 2013 and  ending on June 10, 2013. By 
the end of the data collection period, 125 completed surveys were received by mail and 8 
surveys were returned as undelivered. Thus, 313 surveys were considered delivered 
resulting in a response rate of 39.84% (125/313). Only one mailing was used to collect 
the data. 
3.2 DESCRIPTIVE ANALYSIS 
3.2.1 Respondents’ Demographic and Practice Setting Characteristics 
 Table 3.1 illustrates the demographics and practice setting characteristics of the 
respondents. A total of 76.0% (n = 95) of the respondents were pharmacy directors and 
8.8% (n = 11) were purchasing agents of the hospitals. Approximately half of the 
respondents (47.2%, n = 59) indicated community hospital as their practice setting 
whereas 26.4% (n = 33) worked in a health care system hospital. A majority of the 
respondents, 105 (84.0%), were licensed pharmacists. Regarding the number of 
 43 
pharmacist full-time equivalents (FTEs) employed at each hospital, the majority of the 
respondents (61.6%, n = 77)) indicated 10 or less pharmacist FTEs, 28.0% (n = 35) listed 
between 11 and 25 pharmacist FTEs. A total of 78 (62.4%) respondents reported 10 or 
less full-time equivalent pharmacy technicians and 34 (27.2%) listed between 11 and 25 
FTE pharmacy technicians employed. In terms of facility size, reported as number of 
beds, approximately half of the respondents (42.4%, n = 53) listed 100 or less, whereas 
16.0% (n = 20) indicated between 100 and 150 beds. Of the total 125 respondents, 43 
(34.4%) had less than $1.5 million annual inpatient budget, 48 (38.4%) reported between 
$1.5 and $5.0 million and 34 (27.2%) had more than $5.0 million. A total of 52 (41.6%) 
hospitals were located in large metropolitan areas whereas 29 (23.3%) were set in 
medium metropolitan areas.  
Table 3.2 depicts respondents’ position controlling for pharmacist licensure 
status.  A total of 123 respondents answered the item on licensure and from this total 105 
(85.4%) were licensed pharmacists. Out of the 11 who indicated being purchasing agents, 
only 2 respondents were licensed pharmacists.  
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Table 3.1: Respondents’ Demographic and Practice Setting Characteristics (N=125)a 
Variable Measure Frequency 
N 
 (%) 
Position Director of Pharmacy 
 
Pharmacy Manager 
 
Pharmaceutical Purchasing Agent 
 
Staff Pharmacist 
 
Pharmacy Technician 
 
Otherc 
 
Total (N) 
95 
(76.0%) 
10 
(8.0%) 
11  
(8.8%) 
2  
(1.6%) 
6  
(4.8%) 
1  
(0.8%) 
125 
Facility Type Community Hospital 
 
Chain Hospital 
 
Children’s Hospital 
 
Health Care Group Hospital 
 
Health Care System Hospital 
 
University Hospital 
 
Otherd 
 
Total (N) 
59  
(47.2%) 
14  
(11.2%) 
5  
(4.0%) 
9  
(7.2%) 
33  
(26.4%) 
1  
(0.8%) 
4  
(3.2%) 
125 
Pharmacy Licensure Licensure 
 
No Licensure 
 
Total (N) 
105  
(85.4%) 
18  
(14.6%) 
123b 
aTotal number of respondents (N) = 125. 
bTwo respondents did not answer this item. 
c‘Other’ position specified by respondent as clinical coordinator. 
d‘Other’ facility type indicated by respondents included long term acute care hospitals, rehabilitation 
hospital and privately owned hospital. 
eFTEs – Full-Time Equivalents. 
fNumber of beds. 
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Table 3.1: Respondents’ Demographic and Practice Setting Characteristics 
(continued) 
Variable Measure Frequency 
N 
(%) 
Pharmacist FTEse Less or equal 10 FTEs 
 
11-25 FTEs 
 
26-50 FTEs 
 
More than 50 FTEs 
 
Total (N) 
77  
(61.6%) 
35  
(28.0%) 
6  
(4.8%) 
7  
(5.6%) 
125 
Pharmacy Technician FTEse Less or equal 10 FTEs 
 
11-25 FTEs 
 
26-50 FTEs 
 
More than 50 FTEs 
 
Total (N) 
78  
(62.4%) 
34  
(27.2%) 
8  
(6.4%) 
5  
(4.0%) 
125 
Facility Sizef 
 
 
 
Less than 100 beds 
 
100-150 beds 
 
151-250 beds 
 
251-350 beds 
 
351-450 beds 
 
More than 450 beds 
 
Total (N) 
53  
(42.4%) 
20  
(16.0%) 
17  
(13.6%) 
16  
(12.8%) 
10  
(8.0%) 
9  
(7.2%) 
125 
aTotal number of respondents (N) = 125. 
bTwo respondents did not answer this item. 
c‘Other’ position specified by respondent as clinical coordinator. 
d‘Other’ facility type indicated by respondents included long term acute care hospitals, rehabilitation 
hospital and privately owned hospital. 
eFTEs – Full-Time Equivalents. 
fNumber of beds. 
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Table 3.1: Respondents’ Demographic and Practice Setting Characteristics 
(continued) 
Variable Measure Frequency 
N 
(%) 
Inpatient Medication Budget Less than $1.5 million 
 
$1.5-$5.0 million 
 
$5.0-$10 million 
 
More than $10 million 
 
Total (N) 
43 
(34.4%) 
48  
(38.4%) 
18  
(14.4%) 
16  
(12.8%) 
125 
Facility Location Rural 
 
Semi-Rural 
 
Semi-Urban 
 
Small Metropolitan 
 
Medium Metropolitan 
 
Large Metropolitan 
 
Total (N) 
6  
(4.8%) 
6  
(4.8%) 
15  
(12.0%) 
17  
(13.6%) 
29  
(23.2%) 
52  
(41.6%) 
125 
aTotal number of respondents (N) = 125. 
bTwo respondents did not answer this item. 
c‘Other’ position specified by respondent as clinical coordinator. 
d‘Other’ facility type indicated by respondents included long term acute care hospitals, rehabilitation   
hospital and privately owned hospital. 
eFTEs – Full-Time Equivalents. 
fNumber of beds. 
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Table 3.2: Frequency Distribution of Pharmacists’ Positions within the Hospitals 
and their Licensure Status (N=123)a 
Positions Pharmacist Licensure Total 
 
N  
(%) 
No 
N  
(%) 
Yes 
N  
(%) 
Director of Pharmacy 1  
(5.6%) 
92  
(87.6%) 
93  
(75.6%) 
Pharmacy Manager 3  
(16.7%) 
7  
(6.7%) 
10  
(8.1%) 
Pharmaceutical Purchasing Agent 9  
(50.0%) 
2  
(1.9%) 
11  
(8.9%) 
Staff Pharmacist 0  
(0.0%) 
2  
(1.9%) 
2  
(1.6%) 
Pharmacy Technician 5  
(27.8%) 
1  
(1.0%) 
6  
(4.9%) 
Other 0  
(0.0%) 
1  
(1.0%) 
1  
(0.8%) 
Totala N (%) 18  
(100%) 
105  
(100%) 
123  
(100%) 
aTotal number of respondents (N) = 123, two respondents did not answer the pharmacy licensure item.  
 
3.2.2 Incidence of Drug Shortages  
 In a closed ended question, respondents were asked to report the number of drug 
shortages encountered within their health facility for the month of April 2013. The 
answer choices provided and the results are depicted in Table 3.3.  A majority of the 
respondents 56 (45.5%) reported 11 or more drug shortages for the month of April 2013, 
followed by 23 (18.7%) indicating between 5 and 6 drug shortages. Thus 64.2% (n = 79) 
of the respondents reported five or more drug shortages in April 2013.  
In a related item respondents were asked to give their opinion as to the extent of the drug 
shortages’ problem. The rating scale used was ‘significant problem’, ‘moderate problem’, 
‘some kind of a problem’, and ‘not much of a problem’. Table 3.4 represents the 
 48 
respondents’ ratings of the degree of the drug shortages’ problem. A majority of the 
respondents, 85 (68.0%) rated the existing drug shortages’ problem as ‘significant’ 
whereas 32 (25.6%) indicated drug shortages to be a ‘moderate problem’. Only one 
respondent (0.8%) thought drug shortages were ‘not much of a problem’. 
 In addition, respondents were given a list of the 15 most recent drugs which had a 
shortage as reported by the ASHP web site and were asked to report whether their 
hospital experienced a shortage for each of the 15 recent drug shortages for April 2013. 
Table 3.5 lists the 15 drug products and shows the percentage of hospitals affected by 
each of the products. At least 40% (n = 50) of the respondents indicated that their hospital 
was affected by nine of the drugs listed; four drugs which included atropine sulfate 
injection, calcium chloride injection, dextrose injection, and sodium bicarbonate injection 
affected over 80% (n = 105) of the hospitals and one drug (Dextrose 50% injection) 
affected more than 90% (n = 118) of the hospitals.  
Table 3.3: Frequency Distribution of the Reported Number of Drug Shortages 
Experienced in the Month of April 2013 (N=123)a 
Number of Drug Shortages 
 
Frequency  
N 
(%) 
1 to 2 1  
(0.8%) 
3 to 4 13  
(10.6%) 
5 to 6 23  
(18.7%) 
7 to 8 13  
(10.6%) 
9 to 10 17  
(13.8%) 
11 or more 56  
(45.5%) 
aTotal number of respondents (N) =123, two respondents did not answer the item. 
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Table 3.4: Respondents were Asked to Rate the Degree of the Drug Shortages’ 
Problem Regarding their Hospital Setting (N=125)a  
Degree of the Drug Shortages’ Problem 
 
Frequency  
N 
(%) 
Not much of a problem 1  
(0.8%) 
Some kind of a problem 7  
(5.6%) 
Moderate problem 32  
(25.6%) 
Significant problem 85  
(68%) 
aTotal number of respondents (N) =125. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50 
Table 3.5: Percentage of Hospitals Affected by each of the 15 Drug Shortages Listed 
on the ASHP Web Site as of April, 2013 (N=124)a, b 
Drug Name  Frequency  
N 
(%) 
Amiodarone HCl Injection 50  
(40.3%) 
Amikacin Injection 62  
(50%) 
Aminophylline Injection 54 
(43.5%) 
Atropine Sulfate Injection 106 
(85.5%) 
Calcium Chloride Injection 105 
(84.7%) 
Cytarabine Injection 17 
(13.7%) 
Dextrose 50% Injection 118 
(95.2%) 
Dopamine Injection 65 
(52.4%) 
Diltiazem Injection 40 
(32.3%) 
Methotrexate Injection 25 
(20.2%) 
Midazolam Injection 49 
(39.5%) 
Norepinephrine Injection 46 
(37.1%) 
Oxymorphone Hydrochloride 10 
(8.1%) 
Odanserton Injection 57 
(46%) 
Sodium Bicarbonate Injection 112 
(90.3%) 
aTotal number of respondents (N) =124, one respondent did not answer the item. 
bTotal percentage is more than 100% because of multiple responses.  
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3.2.3 Managing Drug Shortages 
 A list of management activities was provided to respondents and they were asked 
to indicate if their practice used the listed activities in managing their drug shortages. The 
activities listed in the item were as follows: 
 ‘tracking drug shortages/gathering information’,  
 ‘identifying therapeutic alternatives’,  
 ‘contacting vendors, manufacturers, and group purchasing organizations’,  
 ‘manage inventory/rationing available supplies/prioritizing’,  
 ‘communicating drug information to other health care providers’, and  
 ‘communicating drug shortage information to hospital administration’.  
Respondents also had the opportunity to select “other” as a category and provide 
explanation. “Trading and borrowing” was listed. Table 3.6 presents frequency 
distribution of respondents’ responses regarding the activities applied within their 
practice settings when managing drug shortages. More than 90% of the respondents 
selected all of the listed activities that were applicable to their practice setting when 
managing drug shortages. The activity ‘identifying therapeutic alternatives’ was selected 
by majority of the respondents (n = 122, 97.6%), followed by both ‘manage 
inventory/rationing available supplies/prioritizing’ and ‘communicating drug information 
to other health care providers’ activities (n = 121, 96.8%), ‘contacting vendors, 
manufacturers, and group purchasing organizations’ (n = 117, 93.6%), and 
‘communicating drug shortage information to hospital administration’ (n = 113, 90.4%). 
Two of the respondents (2.4%) specified ‘trading/borrowing’ as an activity practiced at 
their hospital when managing drugs in short supply.  
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Table 3.6: Frequency Distribution of Respondents’ Selection Regarding Activities 
Practiced when Managing Drug Shortages (N=125)a 
Activity Frequency 
N 
(%)b 
Tracking drug shortages/Gathering information 116 
(92.8%) 
Identifying therapeutic alternatives 122  
(97.6%) 
Contacting vendors, manufacturers, and group purchasing 
organizations 
117  
(93.6%) 
Manage inventory/Rationing available supplies/Prioritizing 121  
(96.8%) 
Communicating drug information to other health care providers 121  
(96.8%) 
Communicating drug shortage information to hospital administration 113  
(90.4%) 
Trading/Borrowing 2  
(2.4%) 
aTotal number of respondents (N) = 125. 
bTotal frequency is more than 125 and percentage total is more than 100% because of multiple responses. 
 
  
Respondents were asked to estimate the number of hours per week hospital 
pharmacy personnel spend on managing drug shortages.  Table 3.7 shows the frequency 
distributions of respondents’ responses. A total of 62.9% (n = 78) of the respondents 
spent anywhere from a half day to one and a half days a week (four to 12 hours) on 
managing drug shortage situations. Eighteen respondents (14.5%) indicated that they 
spend 2 or more days a week managing drug shortages. 
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Table 3.7: Frequency Distribution of Respondents’ Responses Regarding Number of 
Hours per Week spent when Managing Drug Shortages (N=124)a 
Number of Hours per Week (hrs/week) Frequency  
N 
(%) 
1 to 3 hrs/week 17  
(13.7%) 
4 to 6 hrs/week 31  
(25.0%) 
7 to 9 hrs/week 24  
(19.4%) 
10 to 12 hrs/week 23  
(18.5%) 
13-15 hrs/week 11  
(8.9%) 
16 hrs/week or more 18  
(14.5%) 
aTotal number of respondents (N) =124, one respondent did not answer the item. 
 
3.2.4 Impact of Drug Shortages 
 To explore the impact drug shortages has had on hospital pharmacy personnel, 
respondents were asked to report whether addition staff were hired as a result of 
increased workload and whether or not hospitals pharmacy personnel were shifted from 
patients’ care activities toward managing drug shortages. Only three respondents (2.4%) 
indicated that they had hired more people because of drug shortage situations. The 
remaining 121 (97.6%) reported that there were no hires as a result of increased workload 
due to drug shortages. Of those who reported hiring additional staff, 2 (1.6%) indicated 
hiring 1 additional personnel and 1 (0.8%) respondent reported hiring 2 additional 
personnel. Controlling for hospital size showed that the two respondents who reported 
hiring one additional personnel each split equally between hospitals with less than 100 
beds and hospitals with greater than 100 beds. On the other hand, the respondent who 
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indicated hiring two additional personnel was representative of hospitals with greater 
than 100 beds.    
 Of the 124 respondents, 76 (61.3%) reported that hospital pharmacy personnel 
have not been shifted from patients’ care activities toward managing drug shortages, 
while 48 (38.7%) confirmed shifting hospital pharmacy personnel from patients’ care 
activities. Twenty (41.7%) of the respondents who reported shifting hospital personnel 
were representatives of hospitals with less than 100 beds whereas twenty-eight (58.3%) 
respondents were representatives of hospitals with greater than 100 beds.  
Respondents who reported shifting hospital pharmacy personnel from patients’ 
care activities toward managing drug shortages within their facility settings were asked to 
select from a list of nine patients’ care activities three patients’ care activities and to rate 
the degree to which these areas were affected. The rating scale used was “1” being highly 
affected, “2” being somewhat affected, and “3” not being affected.  The listed patients’ 
care activities included: 
 practice management 
 medication-use policy development 
 optimizing medication therapy 
 drug product procurement and inventory management 
 preparing, packaging and labeling medications 
 medication delivery 
 monitoring medication use 
 evaluating the effectiveness of the medication-use system and  
 research. 
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Table 3.8 depicts the patients’ care activities  and the responses. A majority of the 
respondents, 20 (54.1%), indicated ‘drug product procurement and inventory 
management’ as highly affected, this was followed by ‘preparing, packaging and labeling 
medications’ (N=12, 32.4%) rated as somewhat affected, and ‘medication delivery’ 
(N=7, 18.9%) as being not affected.  
Table 3.8: Respondents’ Ratings of the Extent to which Patients’ Care Activities 
have been Affected (N=37)a 
Patients’ Care Activities Highly 
Affected 
N  
(%) 
Somewhat 
Affected 
N  
(%) 
Not 
Affected 
N 
(%) 
Drug product procurement and 
inventory management 
20  
(54.1%) 
5  
(13.5%) 
5  
(13.5%) 
Preparing, packaging and labeling 
medications 
5  
(13.5%) 
12  
(32.4%) 
2  
(5.4%) 
Monitoring medication use 
 
4  
(10.8%) 
3  
(8.1%) 
0  
(0.0%) 
Practice management 
 
3  
(8.1%) 
4  
(10.8%) 
3  
(8.1%) 
Optimizing medication therapy 
 
2  
(5.4%) 
3  
(8.1%) 
4  
(10.8%) 
Medication delivery 
 
2  
(5.4%) 
6  
(16.2%) 
7  
(18.9%) 
Medication-use policy development 
 
0  
(0.0%) 
4  
(10.8%) 
2  
(5.4%) 
Research 
 
0  
(0.0%) 
0  
(0.0%) 
5  
(13.5%) 
Evaluating the effectiveness of the 
medication-use system 
0  
(0.0%) 
0  
(0.0%) 
0  
(0.0%) 
Total N (%) 
 
36b  
(97.3%) 
37  
(100.0%) 
28c  
(56.7%) 
aTotal number of respondents (N) = 37, eleven respondents did not answer the item. 
bOne respondent did not indicate  ‘Highly Affected’ patients’ care activity. 
cNine respondents did not indicate  ‘Not Affected’ patients’ care activity. 
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3.2.5 Drug Shortage Supply and Information Resources and Respondents’ 
Opinions on Drug Shortage Causes  
Respondents were asked to rank the top three supply resources used when 
obtaining drugs in short supply using numbers 1 through 3 with “1” being the most 
widely used supply resource, “2” being the second most widely used supply resource, and 
“3” being the third most widely used supply resource. The list of supply resources 
included:  
 purchasing off-contract from current vendor 
 purchase from alternative/secondary vendor 
 borrow from another institution 
 obtain services from group purchasing organization 
 purchase-compounded replacement pharmaceuticals and  
 purchase raw materials to compound replacement pharmaceuticals.  
A total of 116 respondents answered the question and the results are depicted in 
Table 3.9. Forty-eight (41.4%) out of 116 respondents reported purchasing off-contract 
from current vendor as the most widely used supply resource. This was followed by 
purchasing from alternative/secondary vendor (n = 28, 24.1%) and borrowing from 
another institution (n = 25, 21.6%). As of total selections, both purchasing off-contract 
from current vendor and purchasing from alternative/secondary vendor were each 
selected by 90 (77.6%) of the respondents among the first three most widely used supply 
resources, followed by borrowing from another institution 84 (72.4%), purchasing 
compounded replacement pharmaceuticals 57 (49.1%), obtaining services from group 
purchasing organization 19 (16.4%), and purchasing raw materials to compound 
replacement pharmaceuticals 3 (2.6%).  Controlling for hospital size showed that among 
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the 90 respondents who selected purchasing from alternative/secondary vendor as one the 
three most widely used supply resource 39 (43.3%) respondents were representatives of 
hospitals with less than 100 beds, and 51 (56.7%) respondents were representatives of 
hospitals with greater than 100 beds. In addition, controlling for hospital type showed 
that among the 90 respondents who selected purchasing from alternative/secondary 
vendor as one of the three most widely used supply resource 48 (53.3%) respondents 
were representatives of non-chain hospitals whereas 42 (46.7%) respondents were 
representatives of chain hospitals.  
Table 3.9: Respondents’ Ranking of the Most Widely Used Supply Resources when    
Obtaining Drugs in Short Supply (N=116)a 
Supply Resource Most 
Widely 
Used 
N  
(%) 
2nd Most 
Widely 
Used  
N  
(%) 
3rd Most 
Widely 
Used 
N 
(%) 
 
 
 
Nb  
(%) 
Purchase off-contract from current 
vendor 
48  
(41.4%) 
27  
(23.3%) 
15  
(12.9%) 
90 
(77.6%) 
Purchase from alternative/secondary 
vendor  
28  
(24.1%) 
39  
(33.6%) 
23  
(19.8%) 
90 
(77.6%) 
Borrow from another institution 
  
25  
(21.6%) 
28  
(24.1%) 
31  
(26.7%) 
84 
(72.4%) 
Purchase compounded replacement 
pharmaceuticals 
11  
(9.5%) 
15  
(12.9%) 
31  
(26.7%) 
57 
(49.1%) 
Obtain services from group 
purchasing organization  
3  
(2.6%) 
6  
(5.2%) 
10  
(8.6%) 
19 
(16.4%) 
Purchase raw materials to compound 
replacement pharmaceuticals  
1  
(0.9%) 
1  
(0.9%) 
1  
(0.9%) 
3  
(2.6%) 
Total N (%) 
 
116  
(100%) 
116  
(100%) 
111c  
(95.6%) 
aTotal number of respondents (N) = 116, nine respondents did not answer the item.  
bIndicates total frequency of respondents who ranked each supply resource.  
cFive respondents did not indicate  ‘3rd Most Widely Used’ supply resource.  
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Respondents were asked to report the information resources used when gathering 
information about drug shortages. A list of seven answer choices included: American 
Society of Health-System Pharmacists (ASHP); Food and Drug Administration (FDA); 
Centers for Disease Control and Prevention (CDC); Wholesalers; Manufacturers; Group 
purchasing organizations (GPOs); and other. Table 3.10 presents the frequency 
distribution of respondents’ choices. A majority of the respondents, 110 (88.0%), 
reported gathering drug shortages information from wholesalers, followed by ASHP (n = 
107, 85.6%) . Seventy-nine (63.2%) used manufacturers as an information resource, 76 
(60.8%) reported GPOs, 69 (55.2%) stated FDA, 14 (11.2%) indicated CDC, and 10 
(8.8%) selected ‘other’ as an answer choice. Of those selecting ‘other’, 5 (4.0%), 
specified the Risk and Safety Management Alert System (RASMAS) as an information 
resource currently used when seeking information about drug shortages.  
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Table 3.10: Frequency Distribution of Respondents’ Responses Regarding 
Information Resources Used in Collecting Drug Shortages Information (N=125)a 
Information Resource Frequency 
N 
(%)b 
Wholesalers 110  
(88.0%) 
ASHPc 107  
(85.6%) 
Manufacturers 79  
(63.2%) 
GPOsd 76  
(60.8%) 
FDAe 69  
(55.2%) 
CDCf 14  
(11.2%) 
Other 10  
(8.0%) 
RASMASg 5  
(4.0%) 
aTotal number of respondents (N) = 125. 
bTotal frequency is more than 125 and total percentage is more than 100% because of multiple responses.  
cASHP-American Society of Health-System Pharmacists. 
dGPOs-Group purchasing organizations. 
eFDA-Food and Drug Administration. 
fCDC-Centers for Disease Control and Prevention. 
gRASMAS-Risk and Safety Management Alert System. 
 
 
Respondents were asked to rank order the top three common reason for drug 
shortages. A list  of reasons were generated from the literature and respondents were 
asked to rate the top three reasons using the following rating scale: “1” being the most 
common reason, “2” being the second most common reason, and “3” being the third most 
common reason. The seven answer choices provided were: consolidation in the industry; 
raw materials; supply chain issues; manufacturing/regulatory issues, changes in clinical 
practice, business decisions; and unknown. Table 3.11 depicts the results.   
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Sixty-one (51.7%) out of 118 respondents indicated manufacturing/regulatory 
issues as the most common reason of drug shortages, this was followed by business 
decision (n = 39, 33.1%) and consolidation in the industry (n = 10, 8.5%). In terms of 
total mentions, 101 (85.6%) respondents indicated manufacturing/regulatory issues 
among the most common reasons of drug shortages, followed by business decisions 96 
(81.4%), consolidation in the industry 73 (61.9%), raw materials 47 (39.8%), supply 
chain issues 30 (25.4%), unknown 5 (4.2%), and changes in clinical practice 1 (0.8%). 
Table 3.11: Respondents’ Ranking of the Most Common Reasons of Drug Shortages 
(N=118)a 
Reasons Most 
Common 
Reason 
N  
(%) 
2nd Most 
Common 
Reason 
N  
(%) 
3rd Most 
Common 
Reason 
N  
(%) 
 
 
 
Nb  
(%) 
Manufacturing/regulatory 
issues  
61  
(51.7%) 
27  
(22.9%) 
13  
(11.0%) 
101 
(85.6%) 
Business Decisions 39  
(33.1%) 
30  
(25.4%) 
27  
(22.9%) 
96 
(81.4%) 
Consolidation in the 
industry  
10  
(8.5%) 
31  
(26.3%) 
32  
(27.1%) 
73 
(61.9%) 
Raw materials  5  
(4.2%) 
16  
(13.6%) 
26  
(22.0%) 
47 
(39.8%) 
Supply chain issues  2  
(1.7%) 
13  
(11.0%) 
15  
(12.7%) 
30 
(25.4%) 
Unknown 1  
(0.8%) 
0  
(0.0%) 
4  
(3.4%) 
5 
(4.2%) 
Changes in clinical 
practice  
0  
(0.0%) 
1  
(0.8%) 
0  
(0.0%) 
1  
(0.8%) 
Total N (%) 118  
(100%) 
118  
(100%) 
117c  
(99.1%) 
aTotal number of respondents (N) =118, seven respondents did not answer the item. 
bIndicates total frequency of respondents who ranked each reason of drug shortages.  
cOne respondent did not indicate ‘3rd Most Common Reason’. 
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3.2.6 Grey Market Vendors and Drug Shortages  
Respondents were asked to report whether a grey market vendor had contacted 
hospital pharmacy personnel in the last month (April, 2013). Grey market vendors were 
defines as secondary supply channels that are unofficial, unauthorized or unintended by 
the original manufacturer for distribution of medicines. A total of 107, (85.6%), reported 
that grey market vendors have contacted hospital pharmacy personnel in the last month 
(April, 2013), whereas 16 (12.8%) respondents indicated that they were not contacted and 
two (1.6%) answered  ‘Don’t know’. Figure 3.1 shows the percentage of hospitals that 
have been contacted by grey market vendors in the last month (April, 2013). 
 Moreover, respondents who confirmed such contact were asked to estimate the 
number of times they were contacted by grey market vendors in the last month (April 
2013). Table 3.12 represents the frequency distribution of the number of times grey 
market vendors have contacted the hospital pharmacy personnel in the last month (April, 
2013). Seventy-three (68.2%) who reported being contacted by grey market vendors  
gave an estimate of the number of times such contact took place. A total of 34 (31.8%) 
did not answer the question. The reported number of grey market vendors’ contacts 
ranged between 1 and 200 contacts, where the average number was 20.4 (SD = 32.035) 
contacts, the median was 10 (Interquartile Range = 5-20) contacts, and the mode was 10 
contacts for the last month (April, 2013). 
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Figure 3.1: Percentage of Hospitals that have been Contacted by Grey Market 
Vendors in the Last Month (April, 2013), (N=125)a 
aTotal number of respondents (N) = 125.
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Table 3.12: Frequency Distribution of the Number of Times Grey Market Vendors 
have contacted the Hospital Pharmacy Personnel in the Last Month (April, 2013), 
(N=73)a 
Number of times contacted by gray 
market vendor 
Frequency (%) 
1 1 (1.4%) 
2 1 (1.4%) 
3 7 (9.6%) 
4 7 (9.6%) 
5 8 (11.0%) 
6 5 (6.8%) 
7 1 (1.4%) 
8 2 (2.7%) 
9 2 (2.7%) 
10 11 (15.1%) 
11 1 (1.4%) 
12 2 (2.7%) 
14 1 (1.4%) 
15 2 (2.7%) 
20 6 (8.2%) 
22 1 (1.4%) 
25 3 (4.1%) 
30 2 (2.7%) 
35 1 (1.4%) 
45 1 (1.4%) 
50 2 (2.7%) 
80 1 (1.4%) 
100 4 (5.5%) 
200 1 (1.4%) 
Total 73 (100%) 
aTotal number of respondents (N) = 73, thirty-four respondents did not answer the item. 
 
 
 
In addition, respondents were asked to indicate both how often hospital pharmacy 
personnel have been solicited by grey market vendors to buy drugs in short supply and 
how often hospital pharmacy personnel have been solicited by grey market vendors to 
sell drugs in short supply. Table 3.13 depicts the frequencies and percentages of how 
often grey market vendors have contacted hospitals to sell or buy drugs in short supply in 
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the last month (April, 2013). In terms of how often grey market vendors have contacted 
hospital pharmacy personnel to sell drugs in short supply, 57 (53.3%) reported receiving 
contacts on a daily basis, 43 (40.2%) weekly, 5 (4.7%) monthly, and 2 (1.9%) 
respondents indicated getting contacts less than monthly. However, a majority of 
respondents, 82 (76.6%), noted not receiving any contacts from grey market vendors with 
the aim of buying drugs in short supply from their hospital pharmacies, this was followed 
by 9 (8.4%) respondents indicating getting such contacts less than monthly, 8 (7.5%) 
daily, 5 (4.7%) weekly, and 3 (2.8%) respondents reporting receiving contacts monthly.      
 
Table 3.13: How Often Grey Market Vendors have Contacted Hospitals to Sell or 
Buy Drugs in Short Supply in the Last Month (April, 2013), (N=107)a 
Frequency To sell drugs in short 
supply 
N 
(%) 
To buy drugs in short 
supply 
N 
(%) 
Daily 57 
(53.3%) 
8 
(7.5%) 
Weekly 43 
(40.2%) 
5 
(4.7%) 
Monthly 5 
(4.7%) 
3 
(2.8%) 
Less than monthly 2 
(1.9%) 
9 
(8.4%) 
None 0 
(0.0%) 
82 
(76.6%) 
Total N (%) 107 
(100%) 
107 
(100%) 
aTotal number of respondents (N) = 107, total percentage more than 100% due to rounding.  
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Furthermore, 107 respondents who confirmed being contacted by grey market 
vendor in the last month (April, 2013) were asked to rank the three most widely used 
methods by which hospital pharmacy personnel hear about drug products availability 
from the grey market vendors using numbers 1 through 3 with “1” being most widely 
used, “2” being the second most widely used, and “3”being the third most widely used 
method. There were six answer choices: email; fax; telephone; US mail, personal visits; 
and other. Table 3.14 illustrates the respondents’ ranking of the most widely used 
methods when receiving  information on drugs in short supply from grey market vendors. 
Sixty-two (62.0%) out of 107 respondents selected telephone as the most widely used 
method followed by email (n = 27, 27.0%) and fax (n = 10, 10.0%). In terms of total 
mentions, 95 (95.0%) respondents indicated telephone among the most common methods 
to hear about availability of drug products in short supply from grey market vendors, 
followed by fax (n = 82, 82.0%) and email (n = 82, 82.0%), US mail (n = 18, 18.0%), and 
personal visits (n = 4, 4.0%). 
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Table 3.14: Respondents’ Ranking of the Most Widely Used Methods when 
Receiving Information on Drugs in Short Supply from Grey Market Vendors 
(N=100)a 
Methods Most Widely 
Used 
N  
(%) 
2nd Most 
Widely Used 
N  
(%) 
3rd Most 
Widely Used 
N  
(%) 
 
 
Nb 
(%) 
Telephone 62  
(62.0%) 
29  
(29.0%) 
4  
(4.0%) 
95  
(95.0%) 
Fax 10  
(10.0%) 
20  
(20.0%) 
52  
(52.0%) 
82  
(82.0%) 
Email 27  
(27.0%) 
40  
(40.0%) 
15  
(15.0%) 
82  
(82.0%) 
US Mail 0  
(0.0%) 
4  
(4.0%) 
14  
(14.0%) 
18  
(18.0%) 
Personal Visits 1  
(1.0%) 
0  
(0.0%) 
3  
(3.0%) 
4  
(4.0%) 
Total (%) 100  
(100%) 
93c  
(93.0%) 
88d  
(88.0%) 
aTotal number of respondents (N) = 100, seven respondents did not answer the item. 
bIndicates total frequency of respondents who ranked each method.  
cSeven respondents did not indicate ‘2nd Most Widely Used’ method. 
dTwelve respondents did not indicate ‘3rd Most Widely Used’ method. 
 
 
 Finally, respondents were asked to indicate all of their main concerns regarding 
purchasing drug products in short supply from grey market vendors. There were eight 
answer choices: cost; authenticity; reliability; ethical concerns; reputation of vendors; 
storage conditions prior to purchase; institutional policy; and other. Table 3.15 presents 
the frequency distribution of respondents’ main concerns when purchasing drugs in short 
supply from grey market vendors.  A majority of the respondents, 98 (91.6%) reported 
cost as their main concern, this was followed by authenticity (n = 79, 73.8%), storage 
conditions prior to purchase (n = 76, 71.0%), ethical concerns (n = 75, 70.1%), reliability 
(n = 60, 56.1%), reputation of vendors (n = 59, 55.1%), and institutional policy (n = 41, 
38.3%).  
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Table 3.15: Frequency Distribution of Respondents’ Main Concerns when 
Purchasing Drugs in Short Supply from Grey Market Vendors (N=107)a 
Concerns Frequencyb  
N 
(%) 
Cost 98  
(91.6%) 
Authenticity 79  
(73.8%) 
Storage conditions prior to purchase 76  
(71.0%) 
Ethical concerns 75  
(70.1%) 
Reliability 60  
(56.1%) 
Reputation of vendor 59  
(55.1%) 
Institutional Policy 41  
(38.3%) 
aTotal number of respondents (N) = 107. 
bTotal frequency is more than 107 and total percentage is more than 100% because of multiple responses.  
 
 
 
3.2.7 Respondents’ Perceptions about Grey Market Vendors’ Activities Associated 
with Drug Shortages 
Respondents were asked about their perceptions towards grey market vendors’ 
activities associated with drug shortages. Grey market was defined as a secondary supply 
channel that is unauthorized or unintended by the original manufacturer for distribution 
of medicines.  Table 3.16 represents the items and the descriptive statistics on 
respondents’ perceptions about grey market vendor activities associated with drug 
shortages. Respondents were asked to rate 7 items using a five-point Likert-like scale, 
where the following ratings were used: 1 = ‘Strongly Disagree’, 2 = ‘Disagree’, 3 = 
‘Neutral’, 4 = ‘Agree’, and 5 = ‘Strongly Agree’. 
 68 
Of the 125 respondents, 96 (76.8%) ‘strongly agreed’ while 24 (19.2%) ‘agreed’ 
that grey market vendors are more likely to contact health care facility when drug 
shortage exists. The mean ( SD) perception score of the respondents on this item was 
4.69 ( 0.70). When asked whether grey market vendors have the ability to identify and 
obtain drugs in short supply, 57 (45.6%) ‘agreed’ whereas 49 (39.2%) ‘strongly agreed’. 
The mean perception score on the item was 4.16 ( 0.902). A majority of the respondents 
72 (57.6%) out of 125 ‘ strongly agreed’ while 43 (34.4%) ‘agreed’ that grey market 
vendors contribute to the drug shortage crises by buying whatever drug supplies they can 
find on the market. The mean ( SD) was 4.43 ( 0.836). 
Once respondents were inquired whether grey market vendors sell drugs in short 
supply at inflated prices, 110 (88.0%) ‘strongly agreed’ while 12 (9.6%) ‘agreed’. The 
mean ( SD) perception score for this item was 4.82 ( 0.597). Respondents indicated 
that grey market vendors offer drugs in short supply needed to treat critically ill patients 
at largest markups with 83 (66.4%) choosing ‘strongly agree’ and 28 (22.4%) ‘agree’. 
The mean ( SD) perception score of the respondents on this item was 4.52 ( 0.799). 
Out of 125 respondents, 58 (46.4%) ‘strongly agreed’, 43 (34.4%) ‘agreed’ while 
12 (9.6%) indicated ‘neutral’ when asked whether grey market vendors are sometimes the 
only source available for obtaining a drug in shortage. The mean ( SD) perception score 
of the respondents on this item was 4.14 ( 1.045). In addition, respondents were 
requested to indicate their level of agreement on whether the practice of buying drug 
products from grey market vendors should be eliminated. Seventy (56.0%) respondents 
‘strongly agreed’ with this statement, 25 (20.0%) ‘agreed’ while 19 (15.2%) reported 
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‘neutral’. The mean ( SD) perception score of the respondents on this item was 4.20 ( 
1.092). 
 
 
 
 70 
Table 3.16: Frequencies and Descriptive Statistics of Respondents’ Perceptions about Grey Market Vendors’ Activities 
Associated with Drug Shortages (N = 125)a 
Item 
(Question Number) 
Scale Rangeb 
SD 
1 
N 
(%) 
D 
2 
N 
(%) 
N 
3 
N 
(%) 
A 
4 
N 
(%) 
SA 
5 
N 
(%) 
Total 
 
N 
(%) 
Mean 
(S.D.) 
Grey market vendors are more likely to contact 
your facility when drug shortage exists (18a). 
2 
(1.6%) 
1 
(0.8%) 
2 
(1.6%) 
24 
(19.2%) 
96 
(76.8%) 
125 
(100.0%) 
4.69 
(0.70) 
Grey market vendors have the ability to identify 
and obtain drugs in short supply (18b). 
3 
(2.4%) 
4 
(3.2%) 
12 
(9.6%) 
57 
(45.6%) 
49 
(39.2%) 
125 
(100.0%) 
4.16 
(0.90) 
Grey market vendors contribute to the drug 
shortage crises by buying whatever supplies they 
can find on the market (18c). 
2 
(1.6%) 
4 
(3.2%) 
4 
(3.2%) 
 
43 
(34.4%) 
72 
(57.6%) 
125 
(100.0%) 
4.43 
(0.84) 
Grey market vendors sell drugs in short supply at 
inflated prices (18d). 
2 
(1.6%) 
0 
(0.0%) 
1 
(0.8%) 
12 
(9.6%) 
110 
(88.0%) 
125 
(100.0%) 
4.82 
(0.60) 
Grey market vendors offer drugs in short supply 
needed to treat critically ill patients at largest 
markups (18e). 
2 
(1.6%) 
0 
(0.0%) 
12 
(9.6%) 
28 
(22.4%) 
83 
(66.4%) 
125 
(100.0%) 
4.52 
(0.799) 
Grey market vendors are sometimes the only 
source available for obtaining a drug in shortage 
(18f). 
4 
(3.2%) 
8 
(6.4%) 
12 
(9.6%) 
43 
(34.4.%) 
58 
(46.4%) 
125 
(100.0%) 
4.14 
(1.05) 
 
The practice of buying products from grey market 
vendors should be eliminated (18g). 
4 
(3.2%) 
7 
(5.6%) 
19 
(15.2%) 
25 
(20.0%) 
70 
(56.0%) 
125 
(100.0%) 
4.20 
(1.09) 
aTotal number of respondents (N) = 125 
bSD – Strongly Disagree, D – Disagree, N – Neutral, A – Agree, SA – Strongly Agree (coded 1 to 5) 
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3.3 HYPOTHESES TESTING 
 The study’s hypotheses and the statistical test that addresses each hypothesis were 
presented in Table 2.2.  Data analyses were conducted using Chi-square test, two sample 
t-test and One-way ANOVA.  
3.3.1 Regrouped Variables 
 For the purpose of conducting valid chi-square test all variables were regrouped in 
order to achieve an adequate number of respondents in each category. According to 
Cochran the smallest expected number in any group should be 5 or 10 and if this 
condition is not met then neighboring groups should be merged together.72 Table 3.17 
presents the values of the original variables and the regrouped variables. 
The variable ‘number of times hospital pharmacy personnel were contacted by 
grey market vendors’  was collected as a continuous data, yet the normal distribution was 
skewed due to extreme outliers. A sensitivity analysis in which the data were analyzed 
with and without the outliers revealed that the outliers had effect on the median values 
and therefore two categories were created. 
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Table 3.17: Original Variables and Regrouped Variables  
Variable Name Regrouped Values (Original Values) 
Number of drug shortages experienced 1-4 (1-2 and 3-4) 
5-8 (5-6 and 7-8) 
9 or more (9-10 and 11 or more) 
Number of hours per week managing drug 
shortages 
1-6 (1-3 and 4-6)  
7-12 (7-9 and 10-12)  
13 or more (13-15 and 16 or more) 
Number of times hospital pharmacy personnel 
were contacted by grey market vendors 
1-10 (Continues) 
Greater than 10 (Continues) 
Facility size in terms of number of beds Less than 100 (less than 100) 
100-250 (100-150 and 151-250)  
Greater than 250 (251-350, 351-450,  and greater than 450) 
Facility type Chain Hospital (Chain Hospital, Health Care Group Hospital and Health Care 
System Hospital)  
Non Chain Hospital (Community Hospital, Children’s Hospital, University Hospital, 
and Other) 
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Table 3.17: Original Variables and Regrouped Variables (continued) 
Variable Name Regrouped Values (Original Values) 
Position within facility Managers (director of pharmacy and pharmacy manager) 
Staff (pharmaceutical purchasing agent, staff pharmacist, pharmacy technician, 
pharmacy clerk, and other)  
Inpatient medication budget Less than $1.5 million (less than $1.5 million) 
$1.5-5.0 million ($1.5-5.0 million) 
Greater than $5.0 million ($5.0-10 million and greater than $10 million) 
Pharmacist FTEs 10 or less (10 or less) 
11 or more (11-25, 26-50 and greater than 50) 
Pharmacy technician FTEs 10 or less (10 or less) 
11 or more (11-25, 26-50 and greater than 50) 
Facility location Rural/Semi-Urban (Rural, Semi-Rural and Semi-Urban) 
Small/Medium Metropolitan (Small Metropolitan and Medium Metropolitan) 
Large Metropolitan (Large Metropolitan) 
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3.3.2 Chi-square Test  
3.3.2.1 Chi-square Test for Dependent Variable ‘Number of Drug Shortages 
Experienced’  
A chi-square test was used to assess the relationship between the number of drug 
shortages experienced in the last month (April, 2013) controlling for health facility size in 
terms of number of beds, facility type, inpatient medication budget, and facility location. 
Despite regrouping, the chi-square test assessing whether a relationship existed between 
the number of drug shortages experienced by a health care system in the last month 
(April, 2013) and health facility size in terms of number of beds and inpatient medication 
budget could not be utilized because 22.2% of the cells had expected counts less than 5. 
According to Yates et al in order to achieve a good chi-square approximation large 
contingency tables should not have more than 20% of the cells with expected counts less 
than 5 and all individual expected counts should be 1 or greater.73 Therefore the 
independent variables ‘facility size’ and ‘inpatient medication budget’ were regrouped 
again creating two categories for each of the variables. In particular, the new categories 
for the ‘facility size’ variable were ‘less than 100 beds’ and ‘100 beds or more’. The 
categories ‘100-250 beds’ and ‘greater than 250 beds’ were merged. The new categories 
for the ‘inpatient medication budget’ variable were ‘less than $1.5 million’ and ‘$1.5 
million or more’. The categories ‘$1.5-5.0 million’ and ‘greater than $5.0 million’ were 
merged. 
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Interpretation of Results: 
 This section summarizes the hypothesis and the results of chi-square analyses for 
each hypothesis. 
Hypothesis 1 
H01: There is an association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and facility size in terms of number of beds. 
The chi-square analysis (Table 3.18) showed significant relationship between the 
number of drug shortages experienced controlling for facility size (2 = 11.907, n = 123, 
df = 2, p = 0.003). Examination of the cell frequencies showed that 70.4% of the 
hospitals with 100 or more beds have experienced nine or more drug shortages for the 
month of April 2013. Thus the hypothesis was supported. 
 
Table 3.18: Number of Drug Shortages for the Month of April 2013 Controlling for 
Hospital Size (N=123) 
Facility Size Number of Drug Shortages Total  
(%) 1-4 5-8 9 or more 
Less than 100 
beds 
n 11 18 23 52  
(100%) Row % 21.2% 34.6% 44.2% 
100 or more 
beds 
n 3 18 50 71  
(100%) Row % 4.2% 25.4% 70.4% 
Total (%) 14  
(11.4%) 
36  
(29.3%) 
73  
(59.3%) 
123 
 (100%) 
Chi-Square Test: 2 = 11.907, n = 123, df = 2, p = 0.003 
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Hypothesis 2 
H02: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and facility type (Chain and Non - Chain 
hospitals). 
The chi-square analysis (Table 3.19) showed no significant relationship between 
the number of drug shortages experienced controlling for facility type (2 = 3.770, n = 
123, df = 2, p = 0.152). The majority of both Chain (50.9%) and Non-Chain (66.2%) 
hospitals have reported nine or more drug shortages for the month of April 2013. Thus 
the hypothesis was not rejected. 
Table 3.19: Number of Drug Shortages Experienced Controlling for Hospital type 
for the Month of April 2013 (N=123) 
Facility Type Number of Drug Shortages Total  
(%) 1-4 5-8 9 or more 
Non - Chain 
Hospital 
n 5 18 45 68 
(100%) Row % 7.4% 26.5% 66.2% 
Chain Hospital n 9 18 28 55 
(100%) Row % 16.4% 32.7% 50.9% 
Total (%) 14  
(11.4%) 
36 
(29.3%) 
73 
(59.3%) 
123 
(100%) 
Chi-Square Test: 2 = 3.770, n = 123, df = 2, p = 0.152 
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Hypothesis 3 
H03: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and hospital inpatient medication budget. 
The chi-square analysis (Table 3.20) showed significant relationship between the 
number of drug shortages experienced controlling for inpatient medication budget (2 = 
13.249, n = 123, df = 2, p = 0.001). Examination of the cell frequencies showed that 65% 
of the hospitals with inpatient medication budget greater than $1.5 million have 
experienced nine or more drug shortages for the month of April 2013. Thus the 
hypothesis was rejected. 
 
Table 3.20: Number of Drug Shortages for the Month of April 2013 Controlling for 
Inpatient Medication Budget (N=123) 
Inpatient Medication 
Budget 
Number of Drug Shortages Total  
(%) 1-4 5-8 9 or more 
Less than $1.5 
million 
n 11 11 21 43  
(100%) Row % 25.6% 25.6% 48.8% 
$1.5 million or 
more 
n 3 25 52 80  
(100%) Row % 3.8% 31.3% 65.0% 
Total (%) 14  
(11.4%) 
36  
(29.3%) 
73  
(59.3%) 
123 
 (100%) 
Chi-Square Test: 2 = 13.249, n = 123, df = 2, p = 0.001 
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Hypothesis 4 
H04: There is no association between the number of drug shortages experienced by a 
health system in the last month (April, 2013) and facility location (Rural/Semi-Urban, 
Small/Medium Metropolitan and Large Metropolitan). 
Table 3.21 shows that there is a significant association between the number of 
drug shortages experienced and facility location (2 = 12.353, n = 123, df = 4, p = 0.015). 
Examination of the cell frequencies showed that 77.8% of the hospitals located in 
Rural/Semi-Urban areas have experienced nine or more shortages for the month of April 
2013. Drug shortages in hospitals located in large metropolitan areas have split in the 
number of drug shortages compared to the rural area hospitals. Therefore the hypothesis 
was rejected. 
Table 3.21: Number of Drug Shortages Experienced for the Month of April 2013 
Controlling for Hospital Location (N=123) 
Facility Location Number of Drug Shortages Total  
(%) 1-4 5-8 9 or more 
Rural/Semi-
Urban 
n 1 5 21 27 
(100%) Row % 3.7% 18.5% 77.8% 
Small/Medium 
Metropolitan 
n 2 17 26 45 
(100%) Row % 4.4% 37.8% 57.8% 
Large 
Metropolitan 
n 11 14 26 51  
(100%) Row % 21.6% 27.5% 51.0% 
Total (%) 14  
(11.4%) 
36  
(29.3%) 
73  
(59.3%) 
123 
 (100%) 
Chi-Square Test: 2 = 12.353, n = 123, df = 4, p = 0.015 
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3.3.2.2 Chi-square Test for Dependent Variable ‘Number of Hours per Week 
Managing Drug Shortages’ 
A chi-square test was used to assess the relationship between the numbers of 
hours spent per week by hospital pharmacy personnel for the management of drug 
shortages controlling for facility size, number of drug shortages experienced in the last 
month (April, 2013), number of pharmacists FTEs, and pharmacy technicians FTEs.  
Interpretation of Results: 
 The following section will present the results of chi-square analyses for each 
hypothesis. 
Hypothesis 5 
HA5: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages controlling for facility size in terms 
of number of beds. 
Table 3.22 shows the Chi-square analysis of the number of hours spent per week 
controlling for hospital size. The results show a significant association between the 
numbers of hours spent by hospital pharmacy personnel when managing drug shortages 
controlling for facility size (2 = 21.340, n = 124, df = 4, p < 0.001). Examination of the 
cell frequencies showed that 60.4% of the hospitals with beds less than 100 have their 
hospital pharmacy personnel spend between one and six hours per week managing drug 
shortages. The result shows that the hypothesis was supported. 
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Table 3.22: Number of Reported Hours Spent Managing Drug Shortages 
Controlling for Hospital Size (N=124) 
Facility Size Number of Hours (hrs/week) Total  
(%) 1-6 7-12 13 or more 
Less than 100 
beds 
n 32 16 5 53 
(100%) Row % 60.4% 30.2% 9.4% 
100 – 250 beds n 10 16 11 37 
(100%) Row % 27.0% 43.2% 29.7% 
Greater than 
250 beds 
n 6 15 13 34  
(100%) Row % 17.6% 44.1% 38.2% 
Total (%) 48 
(38.7%) 
47  
(37.9%) 
29  
(23.4%) 
123 
 (100%) 
Chi-Square Test: 2 = 21.340, n = 124, df = 4, p < 0.001 
  
Hypothesis 6 
HA6: There is an association between the numbers of hours spend per week by hospital 
pharmacy personnel when managing drug shortages and number of drug shortages 
experienced by the health system in the last month (April, 2013). 
Table 3.23 depicts the chi-square analysis which shows a significant association 
between the numbers of hours spent by hospital pharmacy personnel when managing 
drug shortages and the number of drug shortages encountered by the health system for the 
month of April, 2013 (2 = 28.345, n = 122, df = 4, p < 0.001). Examination of the cell 
frequencies showed that the majority (85.7%) of the hospitals indicating between one and 
four drug shortages for the month of April, 2013 had their hospital pharmacy personnel 
spent between one and six hours per week managing drug shortages. As the total number 
 81 
of drug shortages increased more time was spent on managing drug shortages. 
Hypothesis HA6 was supported.  
Table 3.23: Number of Reported Hours Spent Managing Drug Shortages 
Controlling for the Number of Drug Shortages Experienced for the Month of April 
2013 (N=122) 
Number of Drug 
Shortages 
Number of Hours (hrs/week) Total  
(%) 1-6 7-12 13 or more 
1 - 4 n 12 2 0 14 
(100%) Row % 85.7% 14.3% 0.0% 
5 - 8 n 18 16 2 36 
(100%) Row % 50.0% 44.4% 5.6% 
9 or more n 18 28 28 72 
(100%) Row % 25.0% 38.9% 36.1% 
Total (%) 48 
(39.3%) 
46  
(37.7%) 
28  
(23%) 
122 
 (100%) 
Chi-Square Test: 2 = 28.345, n = 122, df = 4, p < 0.001 
 
Hypothesis 7 
HA7: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and number of pharmacist FTEs. 
Table 3.24 depicts the relationship between hours spent by hospital pharmacy 
personnel managing drug shortages controlling for number for pharmacist FTEs. The 
Chi-square analysis showed a significant association between the numbers of hours spent 
by hospital pharmacy personnel when managing drug shortages and the number of 
pharmacists FTEs (2 = 16.069, n = 124, df = 2, p < 0.001). Examination of the cell 
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frequencies showed that the majority (51.9%) of the hospitals with ten or less pharmacy 
technicians FTEs reported that their hospital pharmacy personnel spent between one and 
six hours per week managing drug shortages while the majority (46.8%) of the hospitals 
with eleven or more pharmacists FTEs indicated that that their hospital pharmacy 
personnel spent between seven and twelve hours per week managing drug shortages. 
Hypothesis HA7 was supported. 
 
Table 3.24: Number of Reported Hours Spent Managing Drug Shortages 
Controlling for the Number of Pharmacists FTEs  (N=124) 
Pharmacists FTEs Number of Hours (hrs/week) Total 
(%) 1-6 7-12 13 or more 
10 or less n 40 25 12 77 
(100%) Row % 51.9% 32.5% 15.6% 
11 or more n 8 22 17 47 
(100%) Row% 18.2% 46.8% 36.3% 
Total (%) 48 
(38.7%) 
47 
(37.9%) 
29 
(23.4%) 
124 
(100%) 
Chi-Square Test: 2 = 16.069, n = 124, df = 2, p < 0.001 
 
Hypothesis 8 
HA8: There is an association between the numbers of hours spent per week by hospital 
pharmacy personnel when managing drug shortages and number of pharmacy 
technicians FTEs. 
Table 3.25 depicts the relationship between reported number of hours spent 
managing drug shortages and number of full-time-equivalent (FTE) pharmacy technician 
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employees.  Chi-square analysis showed a significant association between the numbers of 
hours spent by hospital pharmacy personnel when managing drug shortages and the 
number of pharmacy technicians FTEs (2 = 16.935, n = 124, df = 2, p < 0.001). 
Examination of the cell frequencies showed that 51.3% of the hospitals with ten or less 
pharmacy technicians FTEs reported that their hospital pharmacy personnel spent 
between one and six hours per week managing drug shortages while 47.0% of the 
hospitals with eleven or more pharmacy technician FTEs indicated that that their hospital 
pharmacy personnel spent between seven and twelve hours per week managing drug 
shortages. Hypothesis HA8 was supported. 
 
Table 3.25: Numbers of Reported Hours Spent Managing Drug Shortages 
Controlling for the Number of Pharmacy Technicians FTEs  (N=124) 
Pharmacy Technicians 
FTEs 
Number of Hours (hrs/week) Total 
(%) 1-6 7-12 13 or more 
10 or less n 40 27 11 78 
(100%) Row % 51.3% 34.6% 14.1% 
11 or more n 8 20 18 46 
(100%) Row% 17.4% 47.0% 39.1% 
Total (%) 48 
(38.7%) 
47 
(37.9(%) 
29 
(23.4%) 
124 
(100%) 
Chi-Square Test: 2 = 16.935, n = 124, df = 2, p < 0.001 
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3.3.2.3 Chi-square Test for Dependent Variable ‘Number of Times Hospital Pharmacy 
Personnel were Contacted by Grey Market Vendors’  
 
A chi-square test was used to assess the relationship between the numbers of 
times hospital pharmacist personnel were contacted by grey market vendors across 
facility sizes in terms of number of beds, number of drug shortages experienced by a 
health care systems in the last month (April, 2013), facility types, and facility locations. 
Interpretation of Results: 
 The following section will present the results of chi-square analyses for each 
hypothesis. 
Hypothesis 9 
H09: There is no association between the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors across facility sizes in terms of number of beds. 
Table 3.26 depicts the relationship between the numbers of times hospital 
pharmacy personnel were contacted by grey market vendors controlling for hospital size. 
The chi-square analysis showed no significant relationship (2 = 1.963, n = 73, df = 2, p = 
0.375). Examination of cell frequencies showed that more than 50% of the hospitals 
regardless of their facility size were contacted between one and ten times by grey market 
vendors in the month of April, 2013. However, size of the hospital  was not related to the 
number of contacts thus hypothesis H09 was not rejected. 
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Table 3.26: Numbers of Times Hospital Pharmacy Personnel were Contacted by 
Grey Market Vendors Controlling for Facility Size (N=73) 
Facility Size  Number of Grey Market 
Contacts 
Total 
(%) 
1 - 10 Greater than 
10 
Less than 100 
beds 
N 22 10 32 
(100%) Row % 68.8% 31.3% 
100 – 250 beds N 12 7 19 
(100%) Row % 63.2% 36.8% 
Greater than 250 
beds 
N 11 11 22 
(100%) Row % 50.0% 50.0% 
Total (%) 45  
(61.6%) 
28 
(38.4%) 
73 
(100%) 
Chi-Square Test: 2 = 1.963, n = 73, df = 2, p = 0.375 
 
 
Hypothesis 10 
H010: There is no association between the numbers of times hospital pharmacist 
personnel were contacted by grey market vendors controlling for the number of shortages 
experienced by the health system in the last month (April, 2013).  
Table 3.27 depicts the relationship between the numbers of times hospital 
pharmacy personnel were contacted by grey market vendors and the number of drug 
shortages experienced for the month of April, 2013. The chi-square analysis showed no 
significant relationship (2 = 4.340, n = 72, df = 2, p = 0.114). The number of drug 
shortages was not related to the number of contacts by grey market vendors. In 
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examining Table 3.27 more than 50% of the hospitals regardless of the number of drug 
shortages they have experienced for the month of April, 2013 they had been contacted 
between one and ten times by grey market vendors during the month of April, 2013. Thus 
H010 was not rejected. 
 
Table 3.27: Numbers of Times Hospital Pharmacy Personnel were Contacted by 
Grey Market Vendors Controlling for the Number of Drug Shortages Experienced 
for the Month of April 2013 (N=72) 
Number of Drug Shortages  Number of Grey Market 
Contacts 
Total 
(%) 
1 - 10 Greater than 
10 
1 - 4 N 6 2 8 
(100%) Row % 75.0% 25.0% 
5 - 8 N 15 4 19 
(100%) Row % 78.9% 21.1% 
9 or more N 24 21 45 
(100%) Row % 53.3% 46.7% 
Total (%) 45 
(62.5%) 
27 
(37.5%) 
72 
(100%) 
Chi-Square Test: 2 = 4.340, n = 72, df = 2, p = 0.114 
 
 
Hypothesis 11 
H011: There is no association between the numbers of times hospital pharmacist 
personnel were contacted by grey market vendors and the facility type (Chain and Non-
Chain hospitals). 
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Table 3.28 depicts the relationship between the numbers of times hospital 
pharmacy personnel were contacted by grey market vendors and the facility type. The 
chi-square analysis showed no significant relationship between the two variables (2 = 
1.652, n = 73, df = 1, p = 0.199). Thus, hypothesis H011 was not rejected.  The majority of 
both Chain (69.7%) and Non - Chain (55.0%) hospitals reported being contacted between 
one and ten times by grey market vendors for the month of April 2013. 
Table 3.28: Numbers of Times Hospital Pharmacy Personnel were Contacted by 
Grey Market Vendors Controlling for the Facility Type (N=73) 
Facility Type Number of Grey Market 
Contacts 
Total 
(%) 
1 - 10 Greater than 
10 
Non – Chain 
Hospitals 
N 22 18 40 
(100%) Row % 55.0% 45.0% 
Chain Hospitals N 23 10 33 
(100%) Row % 69.7% 30.3% 
Total (%) 45 
(61.6%) 
28 
(38.4%) 
73 
(100%) 
Chi-Square Test: 2 = 1.652, n = 73, df = 1, p = 0.199 
 
Hypothesis 12 
H012: There is no association between the numbers of times hospital pharmacist 
personnel got contacted by grey market vendors by and facility location (Rural/Semi-
Urban, Small/Medium Metropolitan and Large Metropolitan).    
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Table 3.29 shows the results of the numbers of times hospital pharmacy personnel 
were contacted by grey market vendors controlling for hospital location. The chi-square 
analysis showed no significant relationship between the numbers of times hospital 
pharmacy personnel were contacted by grey market vendors and facility location (2 = 
3.442, n = 73, df = 2, p = 0.179). Examination of cell frequencies showed that more than 
50% of the hospitals regardless of their facility location had been contacted between one 
and ten times by grey market vendors for the month of April, 2013. Hypothesis H012 was 
not rejected. 
 
Table 3.29: Numbers of Times Hospital Pharmacy Personnel were Contacted by 
Grey Market Vendors Controlling for the Facility Location (N=73) 
Facility Location Number of Grey Market 
Contacts 
Total 
(%) 
1 - 10 Greater than 
10 
Rural/Semi-
Urban 
N 11 10 22 
(100%) Row % 52.4% 47.6% 
Small/Medium 
Metropolitan 
N 21 7 28 
(100%) Row % 75.0% 25.0% 
Large 
Metropolitan 
N 13 11 24 
(100%) Row % 54.2% 45.8% 
Total (%) 45 
(61.6%) 
28 
(38.4%) 
73 
(100%) 
Chi-Square Test: 2 = 3.442, n = 73, df = 2, p = 0.179 
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3.3.3 Two-sample T-test 
 A two-sample T-test was used to test the following set of hypotheses. 
H013: There is no difference in the mean opinion score of hospital pharmacy personnel 
98whatever supplies they can find on the market controlling for position within the 
facility (Managers and Staff). 
H014: There is no difference in the mean perception score of hospital pharmacy personnel 
in regard to grey market vendors’ practice of selling drugs in short supply at inflated 
prices by their position within the facility (Managers and Staff). 
H015: There is no difference in the mean opinion score of hospital pharmacy personnel 
toward elimination of the practice of buying drugs in short supply from grey market 
vendors by their position within the facility (Managers and Staff).  
 Table 3.30 shows the perception items, the descriptive statistics and the t-test 
results in comparing the mean perception scores of respondents toward grey market 
activities associated with drug shortages controlling for respondent position within the 
healthcare facility. As mentioned earlier, respondents’ positions were re-categorized into 
two categories, managers and staff, due to inadequate cell size numbers when controlling 
for other variables. For each of the three perception measures no statistical significant 
differences were found controlling for manager and staff position. Thus hypotheses  H013, 
H014 and H015 were not rejected. 
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Table 3.30: Respondents’ Perception Scores on Grey Market Activities Controlling 
for  Managers and Staff Positions (N=125) 
Dependent Variables Position df t Sig. 
Managers 
(N = 105) 
Staff 
(N = 20) 
Mean         SD Mean        SD 
Grey market vendors 
contribute to the drug 
shortage crises by 
buying whatever 
supplies they can find 
on the market 
 
 
 
4.47            0.79 
 
 
4.25          1.07 
 
 
123 
 
 
1.06 
 
 
0.29 
Grey market vendors 
sell drugs in short 
supply at inflated 
pricesa 
 
 
4.86            0.49 
 
4.65          0.99 
 
20.81 
 
0.92 
 
0.37 
The practice of buying 
products from grey 
market vendors should 
be eliminated 
 
 
 
4.19             1.13 
 
 
4.25        0.91 
 
 
123 
 
 
-0.22 
 
 
 
0.82 
Dependent variables were measured on 5-point Likert scale ranging 1 to 5 (1 = ‘Strongly Disagree’ and 5 = 
‘Strongly Agree’) 
aEqual variances not assumed 
SD – Standard Deviation 
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3.3.4 One-way ANOVA 
 A one-way analysis of variance was employed to test the following set of 
hypothesis. 
H013: There is no difference in the mean opinion score of hospital pharmacy personnel 
whether grey market vendors contribute toward the drug shortages crises by buying 
whatever supplies they can find on the market controlling for the number of drug 
shortages experienced by the health system in the last month (April, 2013). 
H014: There is no difference in the mean perception score of hospital pharmacy personnel 
in regard to grey market vendors’ practice of selling drugs in short supply at inflated 
prices by number of drug shortages experienced by the health system in the last month 
(April, 2013). 
H015: There is no difference in the mean opinion score of hospital pharmacy personnel 
toward elimination of the practice of buying products from grey market vendors 
controlling for the number of drug shortages experienced by the health system in the last 
month (April, 2013). 
 Table 3.31 provides the descriptive statistics of the perception scores controlling 
for the three groups of drug shortages (‘1-4’, ‘5-8’ and ‘9 or more’ drug shortages). This 
is followed by Table 3.32, which shows the results of ANOVA. 
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Table 3.31: Respondents’ Mean Perception Scores on Grey Market Activities 
Controlling for the Number of Drug Shortages Experienced by the Health Care 
Facility for the Month of April, 2013 (N=123) 
Dependent Variable Number of Drug Shortages Total 
1 – 4 
N = 14 
5 – 8 
N = 36 
9 or more 
N = 73 
 
N = 123 
 Mean       SD Mean       SD Mean       SD Mean    SD 
Grey market vendors 
contribute to the drug 
shortage crises by 
buying whatever 
supplies they can find 
on the market 
 
 
 
4.36        0.50  
 
 
4.58        0.77 
 
 
4.37        0.92 
 
 
4.43     0.84 
Grey market vendors 
sell drugs in short 
supply at inflated prices 
 
 
4.71        0.47 
 
4.89        0.32 
 
4.84        0.69 
 
4.84     0.58 
The practice of buying 
products from grey 
market vendors should 
be eliminated 
 
 
 
4.14        0.95 
 
 
4.25        1.05 
 
 
4.19        1.15 
 
 
4.20    1.09  
Dependent variables were measured on 5-point Likert scale ranging 1 to 5 (1 = ‘Strongly Disagree’ and 5 = 
‘Strongly Agree’) 
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Table 3.32: Respondents’ Perception Scores on Grey Market Activities Controlling 
for the Number of Drug shortages Experienced by the Health Care Facility for the 
Month of April, 2013 (N=123) 
Dependent Variables Sum of 
Squares 
df Mean 
Square 
F Sig. 
Grey market vendors 
contribute to the drug 
shortage crises by buying 
whatever supplies they 
can find on the market 
 
Between 
Within 
Total 
1.19 
84.98 
86.16 
2 
120 
122 
0.59 
0.71 
0.84 0.44 
Grey market vendors sell 
drugs in short supply at 
inflated prices 
 
Between 
Within 
Total 
0.31 
40.44 
40.75 
2 
120 
122 
0.15 
0.34 
0.46 0.63 
The practice of buying 
products from grey 
market vendors should be 
eliminated 
 
Between 
Within 
Total 
0.14 
145.78 
145.92 
2 
120 
122 
0.07 
1.22 
0.06 0.99 
 
 
 
 
 One-way ANOVA tests showed that there were no statistically significant 
differences in the mean perception scores for each of the three perception items when 
controlling for the number of drug shortages. Thus hypotheses  H013, H014 and H015 were 
supported. 
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3.3.5 Summary of Results of Hypotheses Testing 
 Table 3.33 presents a summary of the results of the hypotheses testing.  
Table 3.33: Summary of Results of Hypotheses Testing 
Hypothesis Results 
H01: There is an association between the 
number of drug shortages experienced by a 
health system in the last month (April, 2013) 
and facility size in terms of number of beds. 
Supported 
H02: There is no association between the 
number of drug shortages experienced by a 
health system in the last month (April, 2013) 
and  facility type (Chain and Non - Chain 
hospitals). 
Not Rejected 
H03: There is no association between the 
number of drug shortages experienced by a 
health system in the last month (April, 2013) 
and hospital inpatient medication budget. 
Rejected 
H04: There is no association between the 
number of drug shortages experienced by a 
health system in the last month (April, 2013) 
and facility location (Urban, Small/Medium 
Metropolitan and Large Metropolitan). 
Rejected 
HA5: There is an association between the 
numbers of hours spend per week by hospital 
pharmacy personnel when managing drug 
shortages and facility size in terms of number 
of beds. 
Supported 
HA6: There is an association between the 
numbers of hours spend per week by hospital 
pharmacy personnel when managing drug 
shortages and number of drug shortages 
experienced by the health system in the last 
month (April, 2013). 
Supported 
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Table 3.33: Summary of Results of Hypotheses Testing (continued) 
Hypothesis Results 
HA7: There is an association between the 
numbers of hours spend per week by hospital 
pharmacy personnel when managing drug 
shortages and number of pharmacist FTEs. 
Supported 
HA8: There is an association between the 
numbers of hours spend per week by hospital 
pharmacy personnel when managing drug 
shortages and number of pharmacy technicians 
FTEs. 
Supported 
H09: There is no association between the 
numbers of times hospital pharmacy personnel 
got contacted by grey market vendors across 
facility sizes in terms of number of beds. 
Not Rejected 
H010: There is no association between the 
numbers of times hospital pharmacist personnel 
got contacted by grey market vendors by 
number of shortages experienced by the health 
system in the last month (April, 2013).  
Not Rejected 
H011:There is no association between the 
numbers of times hospital pharmacist personnel 
got contacted by grey market vendors by 
facility type (Chain and Non-Chain hospitals). 
 
Not Rejected 
H012: There is no association between the 
numbers of times hospital pharmacist personnel 
got contacted by grey market vendors by and 
facility location (Urban, Small/Medium 
Metropolitan and Large Metropolitan). 
 
Not Rejected 
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Table 3.33: Summary of Results of Hypotheses Testing (continued) 
Hypothesis Results 
H013: There is no difference in the mean 
opinion score of hospital pharmacy personnel 
whether grey market vendors contribute toward 
the drug shortages crises by buying whatever 
supplies they can find on the market controlling 
by position within the facility (Managers and 
Staff) and number of drug shortages 
experienced by the health system in the last 
month (April, 2013). 
Not Rejected 
H014: There is no difference in the mean 
perception score of hospital pharmacy 
personnel in regard to grey market vendors’ 
practice of selling drugs in short supply at 
inflated prices by their position within the 
facility (Managers and Staff) and number of 
drug shortages experienced by the health 
system in the last month (April, 2013). 
Not Rejected 
H015: There is no difference in the mean 
opinion score of hospital pharmacy personnel 
toward elimination of the practice of buying 
drugs in short supply from grey market vendors 
by their position within the facility (Managers 
and Staff) and number of drug shortages 
experienced by the health system in the last 
month (April, 2013). 
Not Rejected 
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Chapter Four: Discussion 
 
 This chapter provides a summary of the study results and discussion of the 
significance of these finding with regard to the literature. In addition, the chapter will 
assess the study limitations and provide directions for future research. 
4.1 REVIEW OF RESEARCH QUESTION 
The U.S. hospitals have been combating the problem of drug shortages over the 
past decade. The rapidly increasing frequency of drug shortages has caused difficulties in 
the delivery of optimum health care. Health care facilities, clinicians, patients, and federal 
agencies have tried to tackle the issue, yet drug shortages continue to significantly burden 
all parties involved. The most important implications of drug shortage include delayed 
patient care, adverse outcomes, higher drug costs, and an increased strain on health 
professionals in terms of time and money spent on managing drug shortages. The drug 
shortage issue is further complicated by the practices of “grey market” or opportunistic 
vendors who take advantage of the shortage situation and thus significantly contribute to 
the overall problem of drugs in short supply.   
The issue of increased number of drug shortages has grabbed the national 
attention of the mass media, health professionals, federal and state regulators, health care 
and pharmacy associations, patients and patient groups/associations, and politicians. The 
growing public concern is also evident by the increasing number of published journal 
articles, newspaper articles, and news reports. Yet, more research is needed and the 
results communicated to policy makers, manufacturers, public agencies, wholesaler, and 
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the public in order to improve communication among different parties and to present an 
in depth picture of the problem and its implications. Despite all the publicity, there has 
been no study examining the effect of drug shortages across Texas Hospitals.  
This study was conducted on a sample of pharmacy directors of non-government 
acute care hospitals in the state of Texas. The purpose was to explore the incidence and 
impact of drug shortages across Texas Non-Government Acute Care Hospitals. The 
specific objectives were to assess: the proportion of Texas Non-Government Acute Care 
Hospitals experiencing a drug shortage and the number of shortages experienced in the 
last month (April, 2013); the percentage of Texas Non-Government Acute Care Hospitals 
affected by each of the 15 most recent drug shortages as of March 2013 (according to 
ASHP) for the last month; the average number of hours per week spent by hospital 
pharmacy staff managing drug shortages and the activities associated with managing drug 
shortages; whether additional hospital pharmacy personnel were hired as a result of 
increased workload due to drug shortages; whether hospital pharmacy personnel were 
shifted from patient care activities toward managing drug shortages and which activities 
have been affected the most; and the various supply and informational resources used to 
obtain drugs in short supply and information on drug shortages, as well as respondents’ 
opinions with regard to the most common causes of drug shortages. In addition, the study 
estimated the number of acute care hospitals contacted by grey market vendors in the last 
month (April, 2013), the frequency and the mode of contact, and the concerns and the 
opinions of hospital pharmacy personnel toward grey market activities associated with 
current drug shortages. 
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4.2 STUDY FINDINGS 
4.2.1 Demographic and Practice Setting Characteristics 
 Of the 125 respondents who answered the survey, 95 (76.0%) were pharmacy 
directors, 11 (8.8%) were pharmaceutical purchasing agents and 10 (8.0%) were 
pharmacy managers. A majority of the respondents, 105 (84.0%), were licensed 
pharmacists. In addition, the majority (42.4%) of acute care hospitals in Texas were with 
less than 100 beds, had 10 or fewer pharmacist full-time equivalents (61.6%) and 10 or 
fewer pharmacy technician full-time equivalents (62.4%). The practice setting 
characteristics of our sample are consistent with the characteristics reported in the 2010 
national survey of U.S. health systems conducted by the American Society of Health-
System Pharmacists (ASHP). Their results indicated that  29% of the hospitals were with 
less than 100 beds, had 10 or fewer pharmacist full-time equivalents (53%) and 10 or 
fewer pharmacy technician full-time equivalents (49%).74  
4.2.2 Incidence of Drug Shortages 
 This study found that all surveyed hospitals have experienced at least one drug 
shortage for the month of April 2013. The majority of the hospitals, (45.5%), reported 11 
or more drug shortages, followed by 18.7% indicating between 5 and 6 drug shortages. 
Thus, 64.2% of the respondents reported five or more drug shortages for April 2013. 
These findings are consistent with American Hospital Association (AHA) survey in 
which over a period of six months, 99.5% of hospitals experienced at least one drug 
shortage and 95% of the hospitals reported more than five drug shortages .75 Moreover, 
our results indicated that there is a significant association between the number of drug 
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shortages experienced and the increasing in hospital size (p = 0.003), inpatient 
medication budget (p = 0.001) and hospital location (p = 0.015) with more shortages 
occurring in hospitals with 100 or more beds, with inpatient medication budget of $1.5 
million or more, and located in rural/semi urban areas. One previous study assessed the 
relationship between the number of drug shortages experienced by a health system and its 
size or geographic location and found that a significant association existed between the 
number of drug shortages and hospital size in term of number of beds (p = 0.001).76 
In addition, respondents were given a list of the 15 most recent drug shortages as 
reported by the ASHP web site and were asked to report whether their hospital 
experienced a shortage for April 2013. At least 50% of the respondents indicated that 
their hospital was affected by six of the drugs listed; four drugs affected over 80% of the 
hospitals. These findings are consistent with the results reported by Kaakeh et al. where 
50% of respondents reported that their facilities had experienced a shortage of seven of 
the thirty drugs listed and 80% were affected by three of the drugs.77 In addition, a 
national survey of the impact of drug shortages in acute care hospitals conducted by 
Baumer et al. indicated that almost half, 49%, of the respondents reported encountering a 
shortage for seven of the nine drugs listed.78 
4.2.3 Managing Drug Shortages 
Respondents were asked to indicate whether they use activities such as ‘tracking 
drug shortages/gathering information’, ‘identifying therapeutic alternatives’, ‘contacting 
vendors, manufacturers, and group purchasing organizations’, ‘manage 
inventory/rationing available supplies/prioritizing’, ‘communicating drug information to 
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other health care providers’, and ‘communicating drug shortage information to hospital 
administration’ when managing their drug shortages. A majority, 97.6%, of the 
respondents selected ‘identifying therapeutic alternatives’ as the activity practiced when 
managing drug shortages. This was followed by both ‘manage inventory/rationing 
available supplies/prioritizing’ and ‘communicating drug information to other health care 
providers’ activities (96.8%). These results are consistent with the Baumer et al. survey 
that notes ‘identifying therapeutic alternatives’ as the activity reported by the majority, 
84.6%, of the respondents.79 
Additionally, respondents were asked to estimate the number of hours per week 
hospital pharmacy personnel spend on managing drug shortages considering the activities 
mentioned earlier.  A majority, 62.9%, of the respondents spent anywhere from a half day 
to one and a half days a week (four to 12 hours) on managing drug shortage situations 
whereas 14.5% indicated spending 2 or more days a week managing drug shortages. 
Furthermore, the study found a significant association between the number of hours spent 
per week by hospital pharmacy personnel when managing drug shortages controlling for 
hospital size (p < 0.001), number of drug shortages experienced (p < 0.001), number of 
pharmacist FTEs (p < 0.001), and number of pharmacy technician FTEs (p < 0.001). 
Kaakeh et al. reported similar results where pharmacists indicated spending between 5 
and 20 hours per week and pharmacy technicians between 3 and 17 hours per week 
managing drug shortages.  In addition, a significant relationship was found between the 
amount of time spent managing shortages controlling for hospital size and the total 
number of drug shortages experienced.80 
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4.2.4 Impact of Drug Shortages 
Respondents were asked to report whether addition staff were hired as a result of 
increased workload and whether or not hospitals pharmacy personnel were shifted from 
patients’ care activities toward managing drug shortages. Only 2.4% of the respondents 
indicated that they had hired additional staff of which 1.6% reported hiring one additional 
person and 0.8% indicated hiring two additional people. These results are consistent with 
the findings of Baumer et al. and Kaakeh et al. where 2% indicated creating one or more 
new pharmacist positions and 5% reported adding staff to manage drug shortages 
repectively.81, 82  
In addition, only 38.7% of the respondents confirmed shifting hospital pharmacy 
personnel from patients’ care activities toward managing drug shortages, which is 
consistent with the estimates of Kaakeh et al. where 32% of the respondents reported 
relocation of existence staff.83 Furthermore, our study found that a majority, 54.1%, of the 
respondents, who reported shifting of personnel, indicated ‘drug product procurement and 
inventory management’ as the major patient care activity affected as the result of the staff 
relocation.  
4.2.5 Drug Shortage Supply, Information Resources and Causes 
 When asked to rank the top three supply resources used when obtaining drugs in 
short supply, 41.4% of respondents reported purchasing off-contract from current vendor 
followed by 24.1% purchasing from alternative/secondary vendor. These results are 
consistent with the finding of the ASHP 2003 national survey in which the two most 
widely used supply resources were purchasing off-contract from their current vendor and 
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purchasing from alternative vendor as reported by 75% and 74% of the respondents 
respectively.84 
 Additionally, a majority, 88%, of the respondents indicated wholesalers as their 
main resource when gathering drug shortages information, followed by ASHP (85.6%) 
and manufacturers (63.2%). The 2010 ASHP national survey claimed that the ASHP 
website was the most widely used information source as selected by 89% of the 
respondents, followed by wholesalers websites (84%) and group purchasing website 
(74%).85 A possible explanation for the difference was that hospital pharmacy personnel 
are in constant contact with wholesalers thus receiving information on current drug 
shortages could be a part of the established relationship. 
 Respondents were asked to rank order the three most common reasons for drug 
shortages. More than half, 51.7%, of the respondents indicated manufacturing/regulatory 
issues as the most common reason of drug shortages, followed by business decision 
(33.1%) and consolidation in the industry (8.5%). These results are consistent with the 
findings in a previous study that tracked 224 drug shortages and found that the most 
common reason was manufacturing difficulties (28%), followed by business decision 
(20%), and a supply-and-demand imbalance (10%).86 
4.2.6 Grey Market Vendors 
One of the study objectives was to estimate the number of acute care hospitals 
contacted by grey market vendors, defined as secondary supply channels that are 
unofficial, unauthorized or unintended by the original manufacturer for distribution of 
medicines, in the last month (April, 2013), the frequency and the mode of contact, and the 
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concerns and opinions of hospital pharmacy personnel toward grey market activities 
associated with current drug shortages. The majority, 85.6%, of the respondents reported 
that grey market vendors have contacted hospital pharmacy personnel in the last month 
(April, 2013). The reported number of grey market vendors’ contacts ranged between 1 
and 200 contacts, with an average number of 20.4 contacts, median of 10 contacts, and 
mode of 10 contacts. On the question, “With regard to your practice, how often has 
hospital staff personnel been solicited by grey market vendors to buy their products?” 
more than half, 53.3%, of the respondents reported receiving contacts on a daily basis, 
followed by 40.2% indicating weekly. However, when asked “With regard to your 
practice, how often has hospital staff personnel been solicited by grey market vendors 
who want to purchase products from your pharmacy?” only 23.4% of the respondents 
reported receiving such contacts and requests. Furthermore, respondents ranked the three 
most widely used methods by which hospital pharmacy personnel hear about drug 
products availability from the grey market vendors. A majority, 62%, selected telephone 
as the most widely used method, followed by email (27%) and fax (10%). Finally, 
respondents were asked what their main concerns were with purchasing drug products in 
short supply from grey market vendors. A majority of the respondents, 91.6%, reported 
that cost is their main concern, followed by authenticity (73.8%) and storage conditions 
of the drug products prior to purchase (71.0%). A previous study conducted by the 
Institute for Safe Medication Practices (ISMP) found that more than half, 56%, of the 
respondents reported receiving solicitations on a daily basis from up to 10 different grey 
market vendors who sell drugs in short supply. The study found that 90% were contacts 
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made via phone, 76% by email, and 68% by fax. In addition, the ISMP study found that 
more than 13% of the respondents received proposals from grey market vendors who 
wanted to purchase drugs in short supply from their pharmacy. Furthermore, respondents’ 
main concerns regarding products offered by grey market vendors were authenticity 
(74%), cost (69%), ethical concerns (66%), and storage conditions prior to purchase 
(58%).87 
 Additionally, our study aimed to explore whether a relationship existed between 
the numbers of times hospital pharmacist personnel were contacted by grey market 
vendors across facility sizes in terms of number of beds, number of drug shortages 
experienced by a health care systems in the last month (April, 2013), facility types, and 
facility locations. The results showed no such associations making it evident that the 
frequency of grey market vendors’ contacts are not selective with regard to hospital size, 
type, location, and number of drug shortages experienced.  
4.2.7 Respondents’ Perceptions about Grey Market Vendors’ Activities Associated 
with Drug Shortages 
Using a five-point Likert-like scale, respondents were asked to indicate their level 
of agreement as to whether or not grey market vendors’ contribute toward the drug 
shortages crises by buying whatever supplies they can find on the market, grey market 
vendors’ practice of selling drugs in short supply at inflated prices, and whether the 
practice of buying drug products from grey market vendors should be eliminated. More 
than half, 57.6%, of the respondents ‘strongly agreed’ while 34.4% ‘agreed’ that grey 
market vendors contribute to the drug shortage crises by buying whatever drug supplies 
they can find on the market. Furthermore, a majority, 88%, of the respondents ‘strongly 
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agreed’ while 9.6% ‘agreed’ that grey market vendors sell drugs in short supply at 
inflated prices. These perceptions are consistent with findings in the 2011 Premier survey 
in which over a two-week period 1,745 grey market offers were collected with an average 
markup of 650%.88 Similar results were reported in the ISMP survey on drug shortages, 
which found that 31% of respondents from small, critical access hospitals and 35% of the 
respondents from community hospitals had purchased products from grey market vendors 
with markups of 10 times or more the contract price.89Additionally, more than half, 56%, 
of the respondents expressed their strong agreement toward eliminating the practice of 
buying drug products from grey market vendors, while 20% ‘agreed’ and 15.2% reported 
being ‘neutral’ on the issue. Respondents’ perceptions are in agreement with current calls 
for more stringent federal legislations in which rigid penalties are applied toward price 
gouging and diversion of products.90 
 Finally, our study examined whether respondents’ perceptions toward grey market 
activities associated with drug shortages differ while controlling for respondents’ 
positions and the number of drug shortages experienced by the hospital. The results 
indicated no relationship thus concluding that hospital pharmacy personnel of Texas non-
government acute care hospitals share common perceptions toward grey market vendors 
and the part they play in the drug shortages crises. 
4.3 STUDY LIMITATIONS 
 The interpretation of the study findings should be considered in the light of 
several limitations. First, the study had a cross-sectional design and therefore any 
relationships found among variables might change over time. Second, a sample of Texas 
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non-government acute care hospitals was used, which was relatively small in size and 
thus any generalizations should be done with caution, especially to different types of 
hospitals and hospitals located outside of Texas. Third, the survey was self-administered 
and anonymous and as such verification of the responses was impracticable. In addition, 
respondents provided estimates of time based on recall, which is prone to both 
underestimation and overestimation. 
 As a part of the study, perceptions of hospital pharmacy personnel toward grey 
market vendors’ activities associated with drug shortages were assessed. Hence, we 
cannot be assured that respondents will hold the same views over the time and as with all 
questionnaires questions are susceptible to different interpretations. 
 The study response rate was low (i.e., 39.84%) and non-response bias was not 
accounted for in the study. Thus, selection bias might be a problem since only hospitals 
that are interested in the drug shortages issue might have responded to the survey.   
4.4 CONCLUSION 
 A survey of Texas non-government acute care hospitals revealed that the majority 
of the hospitals experienced five or more drug shortages in April 2013 and directors 
acknowledged the significance of the problem. The results showed that hospital 
pharmacy personnel devote a significant amount of time managing drug shortages, which 
in some instances might lead to relocation of personnel and thus compromising some 
patient care activities.  In addition, the majority of respondents accounted for receiving 
solicitations from grey market vendors on a daily basis with the main purpose to sell 
drugs in short supply at inflated prices. These results are in line with the ongoing alarms 
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of drug shortages’ price gouging calling for immediate actions by all stakeholders. 
Furthermore, the majority of the respondents expressed their strong agreement toward 
eliminating the practice of buying drugs in short supply from grey market vendors and 
thus advocating for stronger regulations regarding distribution of pharmaceutical 
products.  
4.5 DIRECTIONS FOR FUTURE RESEARCHES 
This study focused only on non-government acute care facilities. Future research 
should examine the impact of drug shortages in non-acute-care settings, including home 
care, long-term care, and community pharmacy settings and other types of hospitals such 
as psychiatric and oncology hospitals. In addition, it would be necessary to assess the 
financial burden health systems would anticipate when applying alternative therapies 
once a drug shortage is encountered. Another unexplored area is the impact of the 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 on drug 
shortages. Lastly, a study is needed to determine to what extend hospitals buy drugs from 
grey market vendor and sell drugs to grey market vendors. 
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Appendix I 
Assess the Incidence and Impact of Drug Shortages within 
Texas Non - Government Acute Care Hospitals 
SECTION I: DRUG SHORTAGES EXPERIENCE 
In this section we would like to know more about your experience regarding drug 
shortages. 
 
Please check the appropriate box that corresponds with your answer to the questions 
below. 
 
1. Using the following scale, please estimate the number of drug shortages your 
hospital experienced in the last month.    
  None (Please, skip to Section III, page 10)    
 1-2                     
  3-4          
  5-6   
  7-8   
  9-10  
  11 or more   
  
 
2. In your opinion, please rate the degree of the of drug shortages’ problem regarding 
your hospital setting    
  Significant problem   
  Moderate Problem   
  Some kind of a problem  
  Not much of a problem  
  No problem  
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3. Listed below are 15 of the recent drug shortages as listed on ASHP website as of 
March 2013. Please, check all the medicines that apply to your hospital for which 
shortage has been experienced. 
 Amiodarone HCl Injection 
  Amikacin Injection 
  Aminophylline Injection 
 Atropine Sulfate Injection 
 Calcium Chloride Injection 
 Cytarabine Injection 
 Dextrose 50% Injection 
 Dopamine Injection 
 Diltiazem Injection 
 Methotrexate Injection 
 Midazolam Injection 
 Norepinephrine Injection 
 Oxymorphone Hydrochloride 
 Odanserton Injection 
 Sodium Bicarbonate Injection 
 None 
 
4. Which of the following activities apply to your practice when managing drug 
shortages? Please, check all that apply.  
 Tracking drug shortages/Gathering information 
  Identifying therapeutic alternatives 
  Contacting vendors, manufacturers, and group purchasing organizations 
 Manage inventory/Rationing available supplies/Prioritizing 
  Communicating drug shortage information to other health care providers 
  Communicating drug shortage information to hospital administration 
  Other (please, specify)_____________________________________________ 
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5. Regarding your practice, on average, please estimate the number of hours per week 
hospital pharmacy staff spend managing drug shortages considering all the activities 
mentioned above?       
 1-3 hrs/week   
 4-6 hrs/week  
 7-9 hrs/week  
 10-12 hrs/week  
 13-15 hrs/week  
 More than 16 hrs/week  
 
6. With regard to your practice, have you hired additional staff as a result of increased 
workload due to drug shortages?                     
  
 Yes (please continue with Question 7)      
  No (please skip to Question 8)  
 
7. How many additional staff have you hired as a result of increased workload due to 
drug shortages?  
  
 1 
  2 
  3 
  4 
  Other (please, specify)___________________________________________ 
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8. With regard to your practice, have you shifted hospital pharmacy personnel from 
patients’ care activities toward managing drug shortages?  
 Yes (Please continue with Question 9)  
 No (Please skip to Question 10)                     
 
 
9. Listed below are some of the hospital pharmacy personnel patients’ care activities. 
With regard to your practice, please rate the degree of only three care activities that have 
been affected as a result of shifting hospital pharmacy personnel toward managing drug 
shortages using numbers 1 through 3 with “1” being highly affected, “2” being somewhat 
affected and “3” being not affected.  
 __________ practice management 
__________ medication-use policy development 
__________ optimizing medication therapy  
__________ drug product procurement and inventory management 
__________ preparing, packaging, and labeling medications  
__________ medication delivery 
__________ monitoring medication use 
__________ evaluating the effectiveness of the medication-use system 
__________ research 
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10. Listed below are various resources commonly used while obtaining drugs in short 
supply. In your opinion, please rank only three of the most widely used resources using 
numbers 1 through 3 with “1” being most widely used, “2” second most widely used, and 
“3” third most widely used.  
_________Purchase off-contract from current vendor 
 _________Purchase from alternative/secondary vendor 
 _________Borrow from another institution 
 _________Obtain services from group purchasing organization 
 _________Purchase-compounded replacement pharmaceuticals 
 _________Purchase raw materials to compound replacement pharmaceuticals 
 
 
11. Listed below are various information resources commonly used to obtain information 
on drugs in short supply. Please, check all that apply to your practice when gathering 
information on drug shortages. 
  
 ASHP (American Society of Health System Pharmacists) 
  FDA (Food and Drug Administration) 
  CDC (Centers for Disease Control and Prevention) 
 Wholesalers 
  Manufacturers 
  Group purchasing organizations 
  Other (please, specify)_____________________________________________ 
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12. Various reasons have been mentioned for the drug shortage problem. 
In your opinion, please indicate the top three reasons you think are the causes of the 
drug shortage problem using numbers 1 through 3 with “1” being the most common 
reason, “2” being the second most common reason and “3” being the third most common 
reason. 
 
___________Consolidation in the industry 
 ___________Raw Materials 
 ___________Supply Chain Issues 
 ___________Manufacturing/Regulatory Issues 
 ___________Changes in Clinical Practice 
 ___________Business Decisions (Low Profitability) 
 ___________Unknown 
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SECTION II: “GREY MARKET” VENDORS AND DRUG SHORTAGES  
In this section, we would like to know more about your practice and opinion 
regarding “grey market” vendors’ activities associated with drug shortages. For the 
purpose of getting same perspective we define “grey market” as a secondary supply 
channel that is unofficial, unauthorized or unintended by the original manufacturer 
for distribution of medicines 
 
Please check the appropriate box that corresponds with your answer to the questions 
below. 
 
13. With regard to your facility, have hospital pharmacy staff personnel been contacted 
by a grey market vendor in the last month? 
  Yes (please continue with Question 14) 
 If ‘Yes’, please estimate the number of times contacted by grey market vendors in 
the last month 
 ______________ times contacted by grey market vendors in the last month. 
  No (please skip to question 18, page 9) 
 I don’t know (please skip to question 18, page 9) 
 
 
14. With regard to your practice, how often has hospital pharmacy staff personnel been 
solicited by grey market vendors to buy their products?  
  Daily 
  Weekly 
  Monthly 
  Less than monthly 
  None 
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15. With regard to your practice, how often has hospital pharmacy staff personnel been 
solicited by grey market vendors who want to purchase products from your pharmacy?  
  Daily 
  Weekly 
  Monthly 
   Less than monthly 
  None 
 
16. With regard to your practice, please rank only three of the most widely used methods 
by which hospital pharmacy staff personnel hear about products available from the gray 
market vendors using numbers 1 through 3 with “1” being most widely used, “2” second 
widely used, and “3” third widely used. 
 
 ______Email 
 ______Fax 
 _____ Telephone 
 _____ US mail 
 _____ Personal visits 
 _____ Other (please specify)_____________________________________ 
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17. With regard to your practice, what are the main concerns regarding purchasing 
products from grey market vendors? Please, check all that apply. 
   Cost 
  Authenticity 
  Reliability 
  Ethical concerns 
  Reputation of vendors 
  Storage conditions prior to purchase 
  Institutional policy 
  Other (please specify)_______________________________________ 
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18. We are interested in knowing your perceptions of grey market vendors’ activities 
associated with drug shortages.  
Please, check the appropriate circle indicating your level of agreement with each of the 
following statements by choosing one of the following responses:  
 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
a. Grey market vendors are more 
likely to contact your facility 
when drug shortage exists. 
 
 
 
 
 
 
 
 
 
 
 
b. Grey market vendors have the 
ability to identify and obtain 
drugs in short supply. 
 
 
 
 
 
 
 
 
 
 
 
c. Grey market vendors contribute 
to the drug shortage crises by 
buying whatever supplies they 
can find on the market. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d. Grey market vendors sell drugs 
in short supply at inflated prices. 
 
 
 
 
 
 
 
 
 
 
 
e. Grey market vendors offer 
drugs in short supply needed to 
treat critically ill patients at 
largest markups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
f. Grey market vendors are 
sometimes the only source 
available for obtaining a drug in 
shortage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
g. The practice of buying products 
from grey market vendors should 
be eliminated. 
 
 
 
 
 
 
 
 
 
 
 
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SECTION III: DEMPGRAPHICS AND PRACTICE SETTING INFORMATION 
This section will help gather some information about you and your practice setting. 
 
Please check the appropriate box that corresponds with your answer to the questions 
below or write your response as appropriate. 
 
19. Which of the following best describes the facility where you work? 
 Community Hospital 
 Chain Hospital 
 Children’s Hospital 
 Health Care Group Hospital 
 Health Care System Hospital 
 University Hospital  
 Other (please, specify)____________________________________________ 
 
20. Which of the following best describes your position within the facility where you are 
employed? 
 Director of pharmacy 
 Pharmacy manager 
 Pharmaceutical purchasing agent  
 Staff pharmacist 
 Pharmacy technician 
 Pharmacy clerk 
 Other (please, specify)____________________________________________ 
 
21. Are you a licensed pharmacist? 
  Yes 
  No 
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22. Which of the following best describes the number of pharmacist Full Time 
Equivalents (FTEs) at your facility? 
  Less or equal 10 
  11-25 
  26-50 
  Greater than 50 
 
23. Which of the following best describes the number of pharmacy technician FTEs at 
your facility? 
  Less or equal 10 
  11-25 
  26-50 
  Greater than 50   
 
24. Which of the following best describes your facility size in terms of number of beds? 
  Less than 100 
  100 – 150 beds 
  151 – 250 beds 
  251 - 350 beds 
  351 – 450 beds 
 Greater than 451 
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25. Which of the following best describes your facility inpatient medication budget per 
year?  
  Less than $1.5 million 
  $1.5-5.0 million 
  $5.0-10 million 
  Greater than $10 million 
 
26. Which of the following best describes the location of your facility? 
 Large Metropolitan         (Contains city of 500,000 or more, many suburbs,  
            very    little    open country)  
  Medium Metropolitan     (Contains city of 150,000 to 499,000, several    
             suburbs, some open country) 
 Small Metropolitan         (Contains city of 50,000 to 149,499, few suburbs,  
             considerable open country) 
 Semi-Urban                     (City of 10,000 to 49, 999, few smaller towns and  
              contains much open country) 
 Semi-Rural                       (Contains city of 2,500 to 9,999, one or two smaller  
             towns, mostly open country) 
 Rural                                 (Contains town of less than 2,500, surrounded  
             entirely by open country)  
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27. Please, share any additional comments or concerns regarding drug shortages. 
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
If you would like an aggregate summary of the results, please email Tawfik Rajab at 
tawfikrajab@utexas.edu. 
Please, fold the questionnaire, place it in the envelope provided, and drop it in any 
mailbox. No postage is necessary. 
Thank you for taking the time to participate in this survey! 
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Appendix II 
Dear Pharmacy Director, 
 
U.S. hospitals have been combating the increasing number of drug shortages since 2001. U.S. Food and 
Drug Administration (FDA) and American Society of Health System Pharmacists (ASHP) in collaboration 
with the University of Utah Drug Information Service (UUDIS) have reported 178 and 211 drug shortages 
respectively for the year of 2010. The issue of increased number of drug shortages has grabbed national 
attention of the mass media, health professionals, federal and state regulators, health care and pharmacy 
associations, patients and patient groups/associations, and politicians. Yet, more researches are needed and 
their results communicated to policy makers, manufacturers, public agencies, wholesaler, and public as a 
whole in order to improve communication among different parties and present an in depth picture of the 
problem and its implications. 
 
We, at the University of Texas at Austin, are conducting a research to explore the incidence and impact of 
drug shortages within Texas Non – Government Acute Care Hospitals. Enclosed is a questionnaire, which 
has been designed to gather information in regard to hospital pharmacist personnel experience when 
encountering drug shortages and their practices and opinions regarding grey market vendor activities 
associated with drug shortages. Because you are working for an Acute Care Hospital in the state of Texas, 
we are inviting you to participate in this research by completing the enclosed questionnaire.  Although, 
your participation is voluntary, we hope you will participate so that our results will be representative of 
Texas non-government acute care hospitals.  
 
It will only take 10 minutes to complete the questionnaire. All responses are anonymous and will be kept 
confidential. The questionnaire will not gather any personal/hospital identifying data. Responses will only 
be reported in an aggregated form so that results cannot be traced back to any particular 
respondent/hospital. There is no potential risk anticipated to human subjects involved in the study. 
Completion and return of the questionnaire will represent your consent to participate in this study. 
Participants must be over the age of 18 to participate. 
 
If you have any questions about this project, you may contact Marv Shepherd (512) 471-5607 
marvshepherd@mail.utexas.edu or Tawfik Rajab at tawfikrajab@utexas.edu. If you have questions about 
your rights as a research participant, please contact the Office of Research Support at (512) 471-8871, or 
email orsc@uts.cc.utexas.edu. 
 Thank you for your time and cooperation in participating in this study. 
 
Sincerely, 
Marvin Shepherd, Ph.D.                           Tawfik Rajab, B.Pharm, M.S 
Director                                                                                  Graduate Student  
Center for Pharmacoeconomics Studies                                 Health Outcomes and          
                                                                                                Pharmacy Practice Division 
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